BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579. [PMID: 11307091 DOI: 10.1016/s1091-255x(00)80105-5] [Cited by in Crossref: 1056] [Cited by in F6Publishing: 391] [Article Influence: 52.8] [Reference Citation Analysis]
Number Citing Articles
1 Zhao X, Cui N, Wang X, Cui Y. Surgical strategies in the treatment of chronic pancreatitis: An updated systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017;96:e6220. [PMID: 28248878 DOI: 10.1097/MD.0000000000006220] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
2 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. WJG 2021;27:5851-89. [DOI: 10.3748/wjg.v27.i35.5851] [Reference Citation Analysis]
3 Greer JB, Brand RE. New developments in pancreatic cancer. Curr Gastroenterol Rep. 2011;13:131-139. [PMID: 21258973 DOI: 10.1007/s11894-011-0175-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
4 Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford). 2009;11:282-289. [PMID: 19718354 DOI: 10.1111/j.1477-2574.2009.00055.x] [Cited by in Crossref: 130] [Cited by in F6Publishing: 100] [Article Influence: 11.8] [Reference Citation Analysis]
5 Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, Nagano Y, Tanaka K, Ichikawa Y, Togo S, Kunisaki C, Shimada H. Prognostic factors after resection of pancreatic cancer. World J Surg 2009;33:104-10. [PMID: 19011933 DOI: 10.1007/s00268-008-9807-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 5.3] [Reference Citation Analysis]
6 Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs 2011;29:1057-65. [PMID: 20306339 DOI: 10.1007/s10637-010-9413-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Qin R, Smyrk TC, Reed NR, Schmidt RL, Schnelldorfer T, Chari ST, Petersen GM, Tang AH. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer. Br J Cancer 2015;112:514-22. [PMID: 25584484 DOI: 10.1038/bjc.2014.659] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
8 Kim JH, Choi EK, Yoon HK, Ko GY, Sung KB, Gwon DI. Transcatheter arterial chemoembolization for hepatic recurrence after curative resection of pancreatic adenocarcinoma. Gut Liver 2010;4:384-8. [PMID: 20981218 DOI: 10.5009/gnl.2010.4.3.384] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
9 Domínguez I, Crippa S, Thayer SP, Hung YP, Ferrone CR, Warshaw AL, Fernández-Del Castillo C. Preoperative platelet count and survival prognosis in resected pancreatic ductal adenocarcinoma. World J Surg. 2008;32:1051-1056. [PMID: 18224462 DOI: 10.1007/s00268-007-9423-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
10 Adamska A, Domenichini A, Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci. 2017;18. [PMID: 28640192 DOI: 10.3390/ijms18071338] [Cited by in Crossref: 210] [Cited by in F6Publishing: 173] [Article Influence: 52.5] [Reference Citation Analysis]
11 Habermehl D, Brecht IC, Bergmann F, Welzel T, Rieken S, Werner J, Schirmacher P, Büchler MW, Debus J, Combs SE. Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Radiat Oncol 2013;8:27. [PMID: 23369246 DOI: 10.1186/1748-717X-8-27] [Cited by in Crossref: 36] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
12 Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010;7:e1000307. [PMID: 20644708 DOI: 10.1371/journal.pmed.1000307] [Cited by in Crossref: 151] [Cited by in F6Publishing: 123] [Article Influence: 13.7] [Reference Citation Analysis]
13 Linder S, Boström L, Nilsson B. Pancreatic cancer in sweden 1980-2000: a population-based study of hospitalized patients concerning time trends in curative surgery and other interventional therapies. J Gastrointest Surg 2006;10:672-8. [PMID: 16713540 DOI: 10.1016/j.gassur.2005.10.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
14 Nikfarjam M, Hadj AK, Muralidharan V, Tebbutt N, Fink MA, Jones RM, Starkey G, Vaughan RB, Marshall AW, Christophi C. Biliary stenting versus surgical bypass for palliation of periampullary malignancy. Indian J Gastroenterol 2013;32:82-9. [PMID: 23229915 DOI: 10.1007/s12664-012-0274-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Lloyd S, Chang BW. A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer. J Gastrointest Oncol 2013;4:123-30. [PMID: 23730507 DOI: 10.3978/j.issn.2078-6891.2013.011] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
16 Bachmayer S, Fastner G, Vaszi A, Iglseder W, Kopp P, Holzinger J, Dinnewitzer A, Rinnerthaler G, Gampenrieder SP, Emmanuel K, Greil R, Sedlmayer F, Zehentmayr F. Nonmetastatic pancreatic cancer : Improved survival with chemoradiotherapy > 40 Gy after systemic treatment. Strahlenther Onkol 2018;194:627-37. [PMID: 29497791 DOI: 10.1007/s00066-018-1281-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Graversen M, Detlefsen S, Bjerregaard JK, Pfeiffer P, Mortensen MB. Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Clin Exp Metastasis. 2017;34:309-314. [PMID: 28516306 DOI: 10.1007/s10585-017-9849-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
18 Brunner TB, Grabenbauer GG, Meyer T, Golcher H, Sauer R, Hohenberger W. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO). BMC Cancer. 2007;7:41. [PMID: 17338829 DOI: 10.1186/1471-2407-7-41] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
19 Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg 2008;12:57-66. [PMID: 18026817 DOI: 10.1007/s11605-007-0403-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
20 Weinberg L, Houli N, Nikfarjam M. Improving outcomes for pancreatic cancer: radical surgery with patient-tailored, surgery-specific advanced haemodynamic monitoring. BMJ Case Rep 2013;2013:bcr2013008910. [PMID: 23632611 DOI: 10.1136/bcr-2013-008910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, Goggins M, Iacobuzio-Donahue C, Berman DM, Laheru D, Jimeno A, Hidalgo M, Maitra A, Matsui W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010;102:340-51. [PMID: 20164446 DOI: 10.1093/jnci/djp535] [Cited by in Crossref: 293] [Cited by in F6Publishing: 265] [Article Influence: 26.6] [Reference Citation Analysis]
22 Mizukami T, Kamachi H, Fujii Y, Matsuzawa F, Einama T, Kawamata F, Kobayashi N, Hatanaka Y, Taketomi A. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model. Oncotarget 2018;9:33844-52. [PMID: 30333914 DOI: 10.18632/oncotarget.26117] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
23 Matsui H, Hazama S, Sakamoto K, Shindo Y, Kanekiyo S, Nakashima M, Matsukuma S, Tokuhisa Y, Iida M, Suzuki N, Yoshimura K, Takeda S, Ueno T, Yoshino S, Oka M, Nagano H. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy. Pancreas 2017;46:994-1002. [PMID: 28697053 DOI: 10.1097/MPA.0000000000000880] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
24 Tummers WS, Groen JV, Sibinga Mulder BG, Farina-Sarasqueta A, Morreau J, Putter H, van de Velde CJ, Vahrmeijer AL, Bonsing BA, Mieog JS, Swijnenburg RJ. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br J Surg. 2019;106:1055-1065. [PMID: 30883699 DOI: 10.1002/bjs.11115] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 31.5] [Reference Citation Analysis]
25 Karachristos A, Esnaola NF. Surgical management of pancreatic neoplasms: what’s new? Curr Gastroenterol Rep. 2014;16:397. [PMID: 25064316 DOI: 10.1007/s11894-014-0397-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
26 Yoon KW, Heo JS, Choi DW, Choi SH. Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma. J Korean Surg Soc 2011;81:394-401. [PMID: 22200040 DOI: 10.4174/jkss.2011.81.6.394] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
27 White RR, Reddy S, Tyler DS. The role of chemoradiation therapy in locally advanced pancreatic cancer. HPB (Oxford). 2005;7:109-113. [PMID: 18333172 DOI: 10.1080/13651820510016506] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Tinkl D, Grabenbauer GG, Golcher H, Meyer T, Papadopoulos T, Hohenberger W, Sauer R, Brunner TB. Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol. 2009;185:557-566. [PMID: 19756421 DOI: 10.1007/s00066-009-1977-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
29 Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337-1344. [PMID: 19418101 DOI: 10.1007/s11605-009-0919-2] [Cited by in Crossref: 243] [Cited by in F6Publishing: 215] [Article Influence: 20.3] [Reference Citation Analysis]
30 Vento P, Mustonen H, Joensuu T, Kärkkäinen P, Kivilaakso E, Kiviluoto T. Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer. World J Gastroenterol 2007;13:2945-51. [PMID: 17589944 DOI: 10.3748/wjg.v13.i21.2945] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
31 Saito K, Isayama H, Sakamoto Y, Nakai Y, Ishigaki K, Tanaka M, Watadani T, Arita J, Takahara N, Mizuno S, Kogure H, Ijichi H, Tateishi K, Tada M, Hasegawa K, Fukayama M, Kokudo N, Koike K. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer. Med Oncol. 2018;35:100. [PMID: 29846849 DOI: 10.1007/s12032-018-1158-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
32 Scholten L, Latenstein AE, Aalfs CM, Bruno MJ, Busch OR, Bonsing BA, Koerkamp BG, Molenaar IQ, Ubbink DT, van Hooft JE, Fockens P, Glas J, DeVries JH, Besselink MG; Dutch Pancreatic Cancer Group. Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables. United European Gastroenterol J 2020;8:865-77. [PMID: 32703081 DOI: 10.1177/2050640620945534] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zimmermann C, Folprecht G, Zips D, Pilarsky C, Saeger HD, Grutzmann R. Neoadjuvant therapy in patients with pancreatic cancer: a disappointing therapeutic approach? Cancers (Basel) 2011;3:2286-301. [PMID: 24212810 DOI: 10.3390/cancers3022286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
34 Zhou G, Liu X, Wang X, Jin D, Chen Y, Li G, Li C, Fu D, Xu W, Wang X. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. Onco Targets Ther 2017;10:1199-206. [PMID: 28280354 DOI: 10.2147/OTT.S116136] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
35 Combs SE, Habermehl D, Kieser M, Dreher C, Werner J, Haselmann R, Jäkel O, Jäger D, Büchler MW, Debus J. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. BMC Cancer 2013;13:419. [PMID: 24034562 DOI: 10.1186/1471-2407-13-419] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
36 Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic carcinogenesis. Pancreatology. 2008;8:110-125. [PMID: 18382097 DOI: 10.1159/000123838] [Cited by in Crossref: 126] [Cited by in F6Publishing: 111] [Article Influence: 9.7] [Reference Citation Analysis]
37 Kang CM, Chung YE, Park JY, Sung JS, Hwang HK, Choi HJ, Kim H, Song SY, Lee WJ. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer. J Gastrointest Surg. 2012;16:509-517. [PMID: 22183861 DOI: 10.1007/s11605-011-1784-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
38 Crane CH, Varadhachary GR, Wolff RA, Fleming JB. Challenges in the study of adjuvant chemoradiation after pancreaticoduodenectomy. Ann Surg Oncol 2010;17:950-2. [PMID: 20012500 DOI: 10.1245/s10434-009-0859-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
39 Galanis C, Zamani A, Cameron JL, Campbell KA, Lillemoe KD, Caparrelli D, Chang D, Hruban RH, Yeo CJ. Resected Serous Cystic Neoplasms of the Pancreas: A Review of 158 Patients with Recommendations for Treatment. J Gastrointest Surg 2007;11:820-6. [DOI: 10.1007/s11605-007-0157-4] [Cited by in Crossref: 142] [Cited by in F6Publishing: 97] [Article Influence: 10.1] [Reference Citation Analysis]
40 Yamamoto T, Yagi S, Kinoshita H, Sakamoto Y, Okada K, Uryuhara K, Morimoto T, Kaihara S, Hosotani R. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol. 2015;21:262-268. [PMID: 25574100 DOI: 10.3748/wjg.v21.i1.262] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 48] [Article Influence: 9.3] [Reference Citation Analysis]
41 Howard T, Krug J, Yu J, Zyromski N, Schmidt C, Jacobson L, Madura J, Wiebke E, Lillemoe K. A Margin-Negative R0 Resection Accomplished With Minimal Postoperative Complications Is the Surgeon's Contribution to Long-Term Survival in Pancreatic Cancer. Journal of Gastrointestinal Surgery 2006;10:1338-46. [DOI: 10.1016/j.gassur.2006.09.008] [Cited by in Crossref: 229] [Cited by in F6Publishing: 200] [Article Influence: 15.3] [Reference Citation Analysis]
42 Holcomb B, Yip-Schneider MT, Matos JM, Dixon J, Kennard J, Mahomed J, Shanmugam R, Sebolt-Leopold J, Schmidt CM. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J Gastrointest Surg. 2008;12:288-296. [PMID: 18049840 DOI: 10.1007/s11605-007-0406-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
43 Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72. [DOI: 10.1038/nrclinonc.2009.236] [Cited by in Crossref: 516] [Cited by in F6Publishing: 459] [Article Influence: 46.9] [Reference Citation Analysis]
44 House MG, Gönen M, Jarnagin WR, D’Angelica M, DeMatteo RP, Fong Y, Brennan MF, Allen PJ. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg. 2007;11:1549-1555. [PMID: 17786531 DOI: 10.1007/s11605-007-0243-7] [Cited by in Crossref: 138] [Cited by in F6Publishing: 119] [Article Influence: 9.9] [Reference Citation Analysis]
45 Kitagawa H, Tajima H, Nakagawara H, Makino I, Miyashita T, Terakawa H, Nakanuma S, Hayashi H, Takamura H, Ohta T. A modification of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the left pancreas: significance of en bloc resection including the anterior renal fascia. World J Surg. 2014;38:2448-2454. [PMID: 24752361 DOI: 10.1007/s00268-014-2572-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
46 VanHouten JP, White RR, Jackson GP. A decision model of therapy for potentially resectable pancreatic cancer. J Surg Res 2012;174:222-30. [PMID: 22079845 DOI: 10.1016/j.jss.2011.08.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
47 Shankar A, Russell RC. Recent advances in the surgical treatment of pancreatic cancer. World J Gastroenterol 2001;7:622-6. [PMID: 11819842 DOI: 10.3748/wjg.v7.i5.622] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
48 Lou X, Li J, Wei YQ, Jiang ZJ, Chen M, Sun JJ. Comparable prevalence of distant metastasis and survival of different primary site for LN + pancreatic tumor. J Transl Med 2020;18:266. [PMID: 32611358 DOI: 10.1186/s12967-020-02438-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, Barnes D, Schmidt CM, Feng Z, Simeone DM. Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg. 2010;251:937-945. [PMID: 20395854 DOI: 10.1097/sla.0b013e3181d7738d] [Cited by in Crossref: 64] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
50 Allendorf JD, Schrope BA, Lauerman MH, Inabnet WB, Chabot JA. Postoperative glycemic control after central pancreatectomy for mid-gland lesions. World J Surg. 2007;31:164-168; discussion 169-170. [PMID: 17171499 DOI: 10.1007/s00268-005-0382-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
51 Hwang IK, Kim H, Lee YS, Kim J, Cho JY, Yoon YS, Han HS, Hwang JH. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. Cancer Sci 2015;106:1408-13. [PMID: 26183380 DOI: 10.1111/cas.12744] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
52 Matthaei H, Hong SM, Mayo SC, Dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Indian J Surg Oncol 2011;2:9-15. [PMID: 22696140 DOI: 10.1007/s13193-011-0073-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Kleespies A, Albertsmeier M, Obeidat F, Seeliger H, Jauch KW, Bruns CJ. The challenge of pancreatic anastomosis. Langenbecks Arch Surg. 2008;393:459-471. [PMID: 18379817 DOI: 10.1007/s00423-008-0324-4] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 6.2] [Reference Citation Analysis]
54 Chuong MD, Boggs DH, Patel KN, Regine WF. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? J Gastrointest Oncol. 2014;5:166-177. [PMID: 24982765 DOI: 10.3978/j.issn.2078-6891.2014.025] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
55 Butler JR, Ahmad SA, Katz MH, Cioffi JL, Zyromski NJ. A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma. HPB (Oxford) 2016;18:305-11. [PMID: 27037198 DOI: 10.1016/j.hpb.2015.11.009] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
56 Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, Olino K, Schulick R, Winter J, Herman JM, Laheru D, Klein AP, Vogelstein B, Kinzler KW, Velculescu VE, Hruban RH. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15:4674-4679. [PMID: 19584151 DOI: 10.1158/1078-0432.ccr-09-0227] [Cited by in Crossref: 242] [Cited by in F6Publishing: 145] [Article Influence: 20.2] [Reference Citation Analysis]
57 Gagovic V, Spier BJ, DeLee RJ, Barancin C, Lindstrom M, Einstein M, Byrne S, Harter J, Agni R, Pfau PR, Frick TJ, Soni A, Gopal DV. Endoscopic ultrasound fine-needle aspiration characteristics of primary adenocarcinoma versus other malignant neoplasms of the pancreas. Can J Gastroenterol 2012;26:691-6. [PMID: 23061060 DOI: 10.1155/2012/761721] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
58 Kimchi ET, Nikfarjam M, Gusani NJ, Avella DM, Staveley-O'Carroll KF. Combined pancreaticoduodenectomy and extended right hemicolectomy: outcomes and indications. HPB (Oxford) 2009;11:559-64. [PMID: 20495707 DOI: 10.1111/j.1477-2574.2009.00087.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
59 Al-Haddad M, Martin JK, Nguyen J, Pungpapong S, Raimondo M, Woodward T, Kim G, Noh K, Wallace MB. Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg. 2007;11:1168-1174. [PMID: 17632763 DOI: 10.1007/s11605-007-0216-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
60 Pugalenthi A, Protic M, Gonen M, Kingham TP, Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Surg Oncol. 2016;113:188-193. [PMID: 26678349 DOI: 10.1002/jso.24125] [Cited by in Crossref: 68] [Cited by in F6Publishing: 49] [Article Influence: 11.3] [Reference Citation Analysis]
61 Dreyer SB, Jamieson NB, Upstill-Goddard R, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative. Defining the molecular pathology of pancreatic body and tail adenocarcinoma. Br J Surg 2018;105:e183-91. [PMID: 29341146 DOI: 10.1002/bjs.10772] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 17.0] [Reference Citation Analysis]
62 Amini N, Spolverato G, Kim Y, Pawlik TM. Trends in Hospital Volume and Failure to Rescue for Pancreatic Surgery. J Gastrointest Surg. 2015;19:1581-1592. [PMID: 25794484 DOI: 10.1007/s11605-015-2800-9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 14.3] [Reference Citation Analysis]
63 Shamamian P, Goldberg JD, Ye XY, Stewart JD, White PJ, Gilvarg C. Evaluation of pro-carboxypeptidase A and carboxypeptidase A as serologic markers for adenocarcinoma of the pancreas. HPB (Oxford) 2006;8:451-7. [PMID: 18333101 DOI: 10.1080/13651820600747907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
64 Kumar J, Reccia I, Sodergren MH, Kusano T, Zanellato A, Pai M, Spalding D, Zacharoulis D, Habib N. Radiofrequency assisted pancreaticoduodenectomy for palliative surgical resection of locally advanced pancreatic adenocarcinoma. Oncotarget 2018;9:15732-9. [PMID: 29644005 DOI: 10.18632/oncotarget.24596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Zhong J, Switchenko J, Behera M, Kooby D, Maithel SK, McDonald MW, Lin JY, Cassidy RJ, El-Rayes B, Landry J, Patel PR. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. Ann Surg Oncol 2018;25:1026-33. [PMID: 29327180 DOI: 10.1245/s10434-017-6322-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, Hodul PJ, Malafa MP, Springett GM, Centeno BA. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol 2016;7:221-7. [PMID: 27034789 DOI: 10.3978/j.issn.2078-6891.2015.075] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
67 Aranha GV, Hodul P, Golts E, Oh D, Pickleman J, Creech S. A comparison of pancreaticogastrostomy and pancreaticojejunostomy following pancreaticoduodenectomy. J Gastrointest Surg. 2003;7:672-682. [PMID: 12850681 DOI: 10.1016/s1091-255x(02)00432-8] [Cited by in Crossref: 74] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
68 Choi HJ, Kang CM, Lee WJ, Song SY, Cho A, Yun M, Lee JD, Kim JH, Lee JH. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer. Yonsei Med J. 2013;54:1377-1383. [PMID: 24142641 DOI: 10.3349/ymj.2013.54.6.1377] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
69 Gerdtsson AS, Wingren C, Persson H, Delfani P, Nordström M, Ren H, Wen X, Ringdahl U, Borrebaeck CA, Hao J. Plasma protein profiling in a stage defined pancreatic cancer cohort - Implications for early diagnosis. Mol Oncol 2016;10:1305-16. [PMID: 27522951 DOI: 10.1016/j.molonc.2016.07.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
70 Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, Fishman E, Hruban RH, Herman JM, Laheru D, Weiss M, Li M, De Jesus-Acosta A, Wolfgang CL, Zheng L. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget 2015;6:36903-10. [PMID: 26372811 DOI: 10.18632/oncotarget.5054] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
71 Wagner M, Gloor B, Ambühl M, Worni M, Lutz JA, Angst E, Candinas D. Roux-en-Y drainage of the pancreatic stump decreases pancreatic fistula after distal pancreatic resection. J Gastrointest Surg 2007;11:303-8. [PMID: 17458602 DOI: 10.1007/s11605-007-0094-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
72 Sharma A, Smyrk TC, Levy MJ, Topazian MA, Chari ST. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018;155:490-500.e2. [PMID: 29723506 DOI: 10.1053/j.gastro.2018.04.025] [Cited by in Crossref: 66] [Cited by in F6Publishing: 45] [Article Influence: 22.0] [Reference Citation Analysis]
73 Chang YT, Wu CC, Shyr YM, Chen TC, Hwang TL, Yeh TS, Chang KP, Liu HP, Liu YL, Tsai MH, Chang YS, Yu JS. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One. 2011;6:e20029. [PMID: 21625447 DOI: 10.1371/journal.pone.0020029] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
74 Zeeshan MS, Ramzan Z. Current controversies and advances in the management of pancreatic adenocarcinoma. World J Gastrointest Oncol 2021;13:472-94. [PMID: 34163568 DOI: 10.4251/wjgo.v13.i6.472] [Reference Citation Analysis]
75 Buchs NC, Addeo P, Bianco FM, Ayloo S, Benedetti E, Giulianotti PC. Robotic versus open pancreaticoduodenectomy: a comparative study at a single institution. World J Surg. 2011;35:2739-2746. [PMID: 21947494 DOI: 10.1007/s00268-011-1276-3] [Cited by in Crossref: 140] [Cited by in F6Publishing: 105] [Article Influence: 15.6] [Reference Citation Analysis]
76 Weledji EP, Enoworock G, Mokake M, Sinju M. How Grim is Pancreatic Cancer? Oncol Rev 2016;10:294. [PMID: 27471581 DOI: 10.4081/oncol.2016.294] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
77 Tavano F, Fontana A, Pellegrini F, Burbaci FP, Rappa F, Cappello F, Copetti M, Maiello E, Lombardi L, Graziano P, Vinciguerra M, di Mola FF, di Sebastiano P, Andriulli A, Pazienza V. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. J Transl Med 2014;12:248. [PMID: 25199538 DOI: 10.1186/s12967-014-0248-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
78 Traverso LW. Pancreatic cancer: surgery alone is not sufficient. Surg Endosc. 2006;20 Suppl 2:S446-S449. [PMID: 16557419 DOI: 10.1007/s00464- 006-0052-1] [Reference Citation Analysis]
79 Xie Q, Jia L, Liu YH, Wei CG. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World J Gastroenterol. 2009;15:737-741. [PMID: 19222100 DOI: 10.3748/wjg.15.737] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
80 Téoule P, Römling L, Schwarzbach M, Birgin E, Rückert F, Wilhelm TJ, Niedergethmann M, Post S, Rahbari NN, Reißfelder C, Ronellenfitsch U. Clinical Pathways For Pancreatic Surgery: Are They A Suitable Instrument For Process Standardization To Improve Process And Outcome Quality Of Patients Undergoing Distal And Total Pancreatectomy? - A Retrospective Cohort Study. Ther Clin Risk Manag 2019;15:1141-52. [PMID: 31632041 DOI: 10.2147/TCRM.S215373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Lavu H, Lengel HB, Sell NM, Baiocco JA, Kennedy EP, Yeo TP, Burrell SA, Winter JM, Hegarty S, Leiby BE, Yeo CJ. A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma. J Am Coll Surg 2015;220:497-508. [PMID: 25667135 DOI: 10.1016/j.jamcollsurg.2014.12.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
82 Russo S, Saif MW. Neoadjuvant therapy for pancreatic cancer: an ongoing debate. Therap Adv Gastroenterol 2016;9:429-36. [PMID: 27366211 DOI: 10.1177/1756283X16646524] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
83 Caravatta L, Sallustio G, Pacelli F, Padula GD, Deodato F, Macchia G, Massaccesi M, Picardi V, Cilla S, Marinelli A, Cellini N, Valentini V, Morganti AG. Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer. Radiat Oncol 2012;7:86. [PMID: 22691275 DOI: 10.1186/1748-717X-7-86] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
84 Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54:385-7. [PMID: 15710987 DOI: 10.1136/gut.2004.047191] [Cited by in Crossref: 233] [Cited by in F6Publishing: 213] [Article Influence: 14.6] [Reference Citation Analysis]
85 Ying JE, Zhu LM, Liu BX. Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol. 2012;18:736-745. [PMID: 22371633 DOI: 10.3748/wjg.v18.i8.736] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
86 Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev. 2013;4:CD008370. [PMID: 23633353 DOI: 10.1002/14651858.cd008370.pub3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
87 Kobayashi M, Mizuno S, Murata Y, Kishiwada M, Usui M, Sakurai H, Tabata M, Ii N, Yamakado K, Inoue H, Shiraishi T, Yamada T, Isaji S. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression. Pancreas 2014;43:350-60. [PMID: 24622063 DOI: 10.1097/MPA.0000000000000059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 4.4] [Reference Citation Analysis]
88 Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol. 2017;8:127-138. [PMID: 28280617 DOI: 10.21037/jgo.2016.12.04] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
89 Lin JY, Zhang XM, Kou JT, Fa H, Zhang XX, Dai Y, He Q. Analysis of prognostic factors for pancreatic head cancer according to para-aortic lymph node. Cancer Med. 2016;5:2701-2707. [PMID: 27541833 DOI: 10.1002/cam4.853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
90 Sun W, Leong CN, Zhang Z, Lu JJ. Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 2010;5:28. [PMID: 20398316 DOI: 10.1186/1748-717X-5-28] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
91 Khan AZ, Pitsinis V, Mudan SS. Complete pathological response following down-staging chemoradiation in locally advanced pancreatic cancer: challenging the boundaries. World J Gastroenterol 2007;13:6433-5. [PMID: 18081235 DOI: 10.3748/wjg.v13.i47.6433] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
92 Takemura Y, Ojima H, Oshima G, Shinoda M, Hasegawa Y, Kitago M, Yagi H, Abe Y, Hori S, Fujii-Nishimura Y, Kubota N, Masuda Y, Hibi T, Sakamoto M, Kitagawa Y. Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma. Cancer Med 2021;10:5599-613. [PMID: 34245137 DOI: 10.1002/cam4.4121] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Choi SH, Kim SH, Choi JJ, Kang CM, Hwang HK, Lee WJ. Clinical necessity of the immunohistochemical reassessment of para-aortic lymph nodes in resected pancreatic ductal adenocarcinoma. Oncol Lett 2013;6:1189-94. [PMID: 24179493 DOI: 10.3892/ol.2013.1539] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Roeder F, Timke C, Saleh-Ebrahimi L, Schneider L, Hackert T, Hartwig W, Kopp-Schneider A, Hensley FW, Buechler MW, Debus J, Huber PE, Werner J. Clinical phase I/II trial to investigate neoadjuvant intensity-modulated short term radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy) in patients with primarily resectable pancreatic cancer - NEOPANC. BMC Cancer 2012;12:112. [PMID: 22443802 DOI: 10.1186/1471-2407-12-112] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
95 Kang CM, Lee SH, Lee WJ. Minimally invasive radical pancreatectomy for left-sided pancreatic cancer: current status and future perspectives. World J Gastroenterol. 2014;20:2343-2351. [PMID: 24605031 DOI: 10.3748/wjg.v20.i9.2343] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
96 Okubo S, Suzuki T, Hioki M, Shimizu Y, Toyama H, Morinaga S, Gotohda N, Uesaka K, Ishii G, Takahashi S, Kojima M. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer. Cancer Sci 2021;112:2895-904. [PMID: 33931909 DOI: 10.1111/cas.14914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Jamieson NB, Foulis AK, Oien KA, Dickson EJ, Imrie CW, Carter R, McKay CJ. Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2011;15:512-524. [PMID: 21116727 DOI: 10.1007/s11605-010-1395-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
98 Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CM Jr, Freeman JL. Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg 2006;10:1212-23; discussion 1223-4. [PMID: 17114008 DOI: 10.1016/j.gassur.2006.08.010] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
99 Egorov VI, Petrov RV, Lozhkin MV, Maynovskaya OA, Starostina NS, Chernaya NR, Filippova EM. Liver blood supply after a modified Appleby procedure in classical and aberrant arterial anatomy. World J Gastrointest Surg 2013;5:51-61. [PMID: 23556062 DOI: 10.4240/wjgs.v5.i3.51] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
100 Hindriksen S, Bijlsma MF. Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) 2012;4:989-1035. [PMID: 24213498 DOI: 10.3390/cancers4040989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
101 Holyoake DL, Ward E, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Patel N, Silva M, Mukherjee S, Strauss VY, Odondi L, Fokas E, Melcher A, Hawkins MA. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. BMC Cancer 2016;16:728. [PMID: 27619800 DOI: 10.1186/s12885-016-2765-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
102 Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N. Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg. 2010;34:1908-1915. [PMID: 20376443 DOI: 10.1007/s00268-010-0570-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
103 Schwartz PB, Roch AM, Han JS, Vaicius AV, Lancaster WP, Kilbane EM, House MG, Zyromski NJ, Schmidt CM, Nakeeb A, Ceppa EP. Indication for en bloc pancreatectomy with colectomy: when is it safe? Surg Endosc 2018;32:428-35. [PMID: 28664444 DOI: 10.1007/s00464-017-5700-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
104 Wu F, Chen Y, Zhu J. LHPP suppresses proliferation, migration, and invasion and promotes apoptosis in pancreatic cancer. Biosci Rep 2020;40:BSR20194142. [PMID: 32186702 DOI: 10.1042/BSR20194142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
105 Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-180. [PMID: 17667493 DOI: 10.1097/sla.0b013e3180691579] [Cited by in Crossref: 354] [Cited by in F6Publishing: 125] [Article Influence: 25.3] [Reference Citation Analysis]
106 Galindo J, Gabrielli M, Guerra JF, Cassina JC, Garrido M, Jarufe N, Borghero Y, Madrid J, Zoroquiain P, Roa JC, Martínez J. Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases. World J Surg Oncol 2013;11:37. [PMID: 23379413 DOI: 10.1186/1477-7819-11-37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
107 Wentz SC, Zhao ZG, Shyr Y, Shi CJ, Merchant NB, Washington K, Xia F, Chakravarthy AB. Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol. 2012;4:207-215. [PMID: 23444312 DOI: 10.4251/wjgo.v4.i10.207] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
108 Vitale G, van Eijck CH, van Koetsveld Ing PM, Erdmann JI, Speel EJ, van der Wansem Ing K, Mooij DM, Colao A, Lombardi G, Croze E, Lamberts SW, Hofland LJ. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg 2007;246:259-68. [PMID: 17667505 DOI: 10.1097/01.sla.0000261460.07110.f2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
109 Alizai PH, Mahnken AH, Klink CD, Neumann UP, Junge K. Extended distal pancreatectomy with en bloc resection of the celiac axis for locally advanced pancreatic cancer: a case report and review of the literature. Case Rep Med 2012;2012:543167. [PMID: 22567019 DOI: 10.1155/2012/543167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
110 Winter JM, Narang AK, Mansfield AS, Herman JM, Cameron JL, Laheru D, Eckhauser FE, Olson MT, Hruban RH, Miller RC, Andersen DK. Resectable pancreatic small cell carcinoma. Rare Tumors 2011;3:e5. [PMID: 21464878 DOI: 10.4081/rt.2011.e5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
111 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.1002/caac.21190] [Reference Citation Analysis]
112 Strasberg SM, Gao F, Sanford D, Linehan DC, Hawkins WG, Fields R, Carpenter DH, Brunt EM, Phillips C. Jaundice: an important, poorly recognized risk factor for diminished survival in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford). 2014;16:150-156. [PMID: 23600768 DOI: 10.1111/hpb.12094] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
113 Zheng Z, Wang M, Tan C, Chen Y, Ping J, Wang R, Liu X. Disparities in survival by stage after surgery between pancreatic head and body/tail in patients with nonmetastatic pancreatic cancer. PLoS One 2019;14:e0226726. [PMID: 31856205 DOI: 10.1371/journal.pone.0226726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
114 Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol. 2011;17:867-897. [PMID: 21412497 DOI: 10.3748/wjg.v17.i7.867] [Cited by in CrossRef: 114] [Cited by in F6Publishing: 96] [Article Influence: 11.4] [Reference Citation Analysis]
115 de la Fuente SG, Ceppa EP, Reddy SK, Clary BM, Tyler DS, Pappas TN. Incidence of benign disease in patients that underwent resection for presumed pancreatic cancer diagnosed by endoscopic ultrasonography (EUS) and fine-needle aspiration (FNA). J Gastrointest Surg. 2010;14:1139-1142. [PMID: 20424928 DOI: 10.1007/s11605-010-1196-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
116 Rong Y, Wu W, Ni X, Kuang T, Jin D, Wang D, Lou W. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol. 2013;34:1523-1530. [PMID: 23404405 DOI: 10.1007/s13277-013-0679-1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 11.8] [Reference Citation Analysis]
117 Vollmer CM, Sanchez N, Gondek S, McAuliffe J, Kent TS, Christein JD, Callery MP; Pancreatic Surgery Mortality Study Group. A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg. 2012;16:89-102; discussion 102-3. [PMID: 22065319 DOI: 10.1007/s11605-011-1753-x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 107] [Article Influence: 14.5] [Reference Citation Analysis]
118 Lin ZB, Song JY, Li AC, Chen C, Huang XX, Xu BH. The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis. PLoS One 2020;15:e0243170. [PMID: 33315874 DOI: 10.1371/journal.pone.0243170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Sawicka E, Mirończuk A, Wojtukiewicz MZ, Sierko E. Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question? Contemp Oncol (Pozn) 2016;20:102-8. [PMID: 27358587 DOI: 10.5114/wo.2016.60066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
120 Sohn TA, Yeo CJ, Cameron JL, Geschwind JF, Mitchell SE, Venbrux AC, Lillemoe KD. Pancreaticoduodenectomy: role of interventional radiologists in managing patients and complications. J Gastrointest Surg. 2003;7:209-219. [PMID: 12600445 DOI: 10.1016/s1091-255x(02)00193-2] [Cited by in Crossref: 119] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
121 Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, Makary M, Hirose K, Edil B, Choti MA, Herman J, Cameron JL, Wolfgang CL, Pawlik TM. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:1478-1486. [PMID: 22692586 DOI: 10.1007/s11605-012-1923-5] [Cited by in Crossref: 320] [Cited by in F6Publishing: 271] [Article Influence: 35.6] [Reference Citation Analysis]
122 Mizukami T, Kamachi H, Mitsuhashi T, Tsuruga Y, Hatanaka Y, Kamiyama T, Matsuno Y, Taketomi A. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy. BMC Cancer. 2014;14:687. [PMID: 25240521 DOI: 10.1186/1471-2407-14-687] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
123 Varadhachary GR. Preoperative therapies for resectable and borderline resectable pancreatic cancer. J Gastrointest Oncol. 2011;2:136-142. [PMID: 22811843 DOI: 10.3978/j.issn.2078-6891.2011.030] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
124 Kadhim LA, Dholakia AS, Herman JM, Wahl RL, Chaudhry MA. The role of 18F-fluorodeoxyglucose positron emission tomography in the management of patients with pancreatic adenocarcinoma. J Radiat Oncol 2013;2:341-52. [PMID: 29423019 DOI: 10.1007/s13566-013-0130-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
125 Li G, Chen JZ, Chen S, Lin SZ, Pan W, Meng ZW, Cai XR, Chen YL. Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma. Cancer Med 2020;9:3353-70. [PMID: 32181599 DOI: 10.1002/cam4.2959] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
126 Turrini O, Moutardier V, Guiramand J, Lelong B, Bories E, Sannini A, Magnin V, Viret F, Blache JL, Giovannini M, Delpero JR. Hemorrhage after duodenopancreatectomy: impact of neoadjuvant radiochemotherapy and experience with sentinel bleeding. World J Surg. 2005;29:212-216. [PMID: 15654661 DOI: 10.1007/s00268-004-7557-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
127 Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford). 2009;11:282-289. [PMID: 19718354 DOI: 10.1111/j. 1477-2574.2009.00055.x] [Reference Citation Analysis]
128 Hutteman M, van der Vorst JR, Mieog JS, Bonsing BA, Hartgrink HH, Kuppen PJ, Löwik CW, Frangioni JV, van de Velde CJ, Vahrmeijer AL. Near-infrared fluorescence imaging in patients undergoing pancreaticoduodenectomy. Eur Surg Res. 2011;47:90-97. [PMID: 21720166 DOI: 10.1159/000329411] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
129 Rotolo S, Ferracci F, Santullo F, Lodoli C, Inzani F, Abatini C, Pacelli F, Di Giorgio A. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases of pancreatic origin. Int J Surg Case Rep 2020;77S:S75-8. [PMID: 33191190 DOI: 10.1016/j.ijscr.2020.10.054] [Reference Citation Analysis]
130 Chari ST. Detecting early pancreatic cancer: problems and prospects. Semin Oncol. 2007;34:284-294. [PMID: 17674956 DOI: 10.1053/j.seminoncol.2007.05.005] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 6.8] [Reference Citation Analysis]
131 Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
132 Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev 2014;257:145-64. [PMID: 24329795 DOI: 10.1111/imr.12141] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
133 Hardacre JM. Is there a learning curve for pancreaticoduodenectomy after fellowship training? HPB Surg 2010;2010:230287. [PMID: 21318116 DOI: 10.1155/2010/230287] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
134 Haddad LB, Scatton O, Randone B, Andraus W, Massault PP, Dousset B, Soubrane O. Pancreatic fistula after pancreaticoduodenectomy: the conservative treatment of choice. HPB (Oxford). 2009;11:203-209. [PMID: 19590648 DOI: 10.1111/j.1477-2574.2009.00007.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
135 Crippa S, Domínguez I, Rodríguez JR, Razo O, Thayer SP, Ryan DP, Warshaw AL, Fernández-del Castillo C. Quality of life in pancreatic cancer: analysis by stage and treatment. J Gastrointest Surg 2008;12:783-93; discussion 793-4. [PMID: 18317851 DOI: 10.1007/s11605-007-0391-9] [Cited by in Crossref: 68] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
136 Sutton JM, Kooby DA, Wilson GC, Squires MH 3rd, Hanseman DJ, Maithel SK, Bentrem DJ, Weber SM, Cho CS, Winslow ER, Scoggins CR, Martin RC 2nd, Kim HJ, Baker JJ, Merchant NB, Parikh AA, Abbott DE, Edwards MJ, Ahmad SA. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg 2014;18:1575-87. [PMID: 24944151 DOI: 10.1007/s11605-014-2567-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
137 Gudjonsson B. Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions. HPB Surg 2016;2016:6839687. [PMID: 27847403 DOI: 10.1155/2016/6839687] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
138 Combs SE, Habermehl D, Kessel K, Bergmann F, Werner J, Brecht I, Schirmacher P, Jäger D, Büchler MW, Debus J. Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. Outcome analysis and comparison with a 3D-treated patient cohort. Strahlenther Onkol 2013;189:738-44. [PMID: 23896630 DOI: 10.1007/s00066-013-0391-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
139 Brunner TB. Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm? Curr Oncol Rep. 2013;15:162-169. [PMID: 23325567 DOI: 10.1007/s11912-012-0291-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
140 Kwak BJ, Kim SC, Song KB, Lee JH, Hwang DW, Park KM, Lee YJ. Prognostic factors associated with early mortality after surgical resection for pancreatic adenocarcinoma. Korean J Hepatobiliary Pancreat Surg 2014;18:138-46. [PMID: 26155266 DOI: 10.14701/kjhbps.2014.18.4.138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
141 Singh G, Nassri A, Kim D, Zhu H, Ramzan Z. Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma. World J Gastrointest Pharmacol Ther. 2017;8:60-66. [PMID: 28217375 DOI: 10.4292/wjgpt.v8.i1.60] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
142 Adsay NV, Basturk O, Altinel D, Khanani F, Coban I, Weaver DW, Kooby DA, Sarmiento JM, Staley C. The number of lymph nodes identified in a simple pancreatoduodenectomy specimen: comparison of conventional vs orange-peeling approach in pathologic assessment. Mod Pathol 2009;22:107-12. [PMID: 18820663 DOI: 10.1038/modpathol.2008.167] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
143 Riall TS, Sheffield KM, Kuo YF, Townsend CM, Goodwin JS. Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. J Am Geriatr Soc. 2011;59:647-654. [PMID: 21453378 DOI: 10.1111/j.1532-5415.2011.03353.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
144 Wolny-Rokicka E, Sutkowski K, Grządziel A, Dorsz Ż, Tukiendorf A, Lipiński J, Wydmański J. Tolerance and efficacy of palliative radiotherapy for advanced pancreatic cancer: A retrospective analysis of single-institutional experiences. Mol Clin Oncol 2016;4:1088-92. [PMID: 27284450 DOI: 10.3892/mco.2016.851] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
145 Van Heek NT, De Castro SM, van Eijck CH, van Geenen RC, Hesselink EJ, Breslau PJ, Tran TC, Kazemier G, Visser MR, Busch OR. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg. 2003;238:894-902; discussion 902-905. [PMID: 14631226 DOI: 10.1097/01.sla.0000098617.21801.95] [Cited by in Crossref: 137] [Cited by in F6Publishing: 89] [Article Influence: 7.6] [Reference Citation Analysis]
146 Dholakia AS, Chaudhry M, Leal JP, Chang DT, Raman SP, Hacker-Prietz A, Su Z, Pai J, Oteiza KE, Griffith ME, Wahl RL, Tryggestad E, Pawlik T, Laheru DA, Wolfgang CL, Koong AC, Herman JM. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014;89:539-46. [PMID: 24751410 DOI: 10.1016/j.ijrobp.2014.02.031] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
147 Distler M, Rückert F, Hunger M, Kersting S, Pilarsky C, Saeger HD, Grützmann R. Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg 2013;13:12. [PMID: 23607915 DOI: 10.1186/1471-2482-13-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
148 Zhong J, Patel K, Switchenko J, Cassidy RJ, Hall WA, Gillespie T, Patel PR, Kooby D, Landry J. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation. Cancer. 2017;123:3486-3493. [PMID: 28493288 DOI: 10.1002/cncr.30706] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 12.5] [Reference Citation Analysis]
149 Li Q, Zhang L, Li X, Yan H, Yang L, Li Y, Li T, Wang J, Cao B. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : HER1-4 protein expression and prognosis in pancreatic cancer. BMC Cancer 2016;16:910. [PMID: 27871278 DOI: 10.1186/s12885-016-2889-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
150 Bhutani MS, Koduru P, Joshi V, Saxena P, Suzuki R, Irisawa A, Yamao K. The role of endoscopic ultrasound in pancreatic cancer screening. Endosc Ultrasound. 2016;5:8-16. [PMID: 26879161 DOI: 10.4103/2303-9027.175876] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
151 Liu Q, Stewart J, Wang H, Rashid A, Zhao J, Katz MH, Lee JE, Fleming JB, Maitra A, Wolff RA, Varadhachary GR, Krishnan S, Wang H. Reduced expression of argininosuccinate synthetase 1 has a negative prognostic impact in patients with pancreatic ductal adenocarcinoma. PLoS One 2017;12:e0171985. [PMID: 28187218 DOI: 10.1371/journal.pone.0171985] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
152 Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology. 2010;10:66-73. [PMID: 20332664 DOI: 10.1159/000231984] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 7.5] [Reference Citation Analysis]
153 Lin C, Verma V, Ly QP, Lazenby A, Sasson A, Schwarz JK, Meza JL, Are C, Li S, Wang S, Hahn SM, Grem JL. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiother Oncol 2019;132:55-62. [PMID: 30825970 DOI: 10.1016/j.radonc.2018.11.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
154 Ullenhag GJ, Rossmann E, Liljefors M. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. PLoS One 2015;10:e0121197. [PMID: 25837499 DOI: 10.1371/journal.pone.0121197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
155 Khanna A, Koniaris LG, Nakeeb A, Schoeniger LO. Laparoscopic spleen-preserving distal pancreatectomy. J Gastrointest Surg. 2005;9:733-738. [PMID: 15862272 DOI: 10.1016/j.gassur.2004.07.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
156 Nuccitelli R, Huynh J, Lui K, Wood R, Kreis M, Athos B, Nuccitelli P. Nanoelectroablation of human pancreatic carcinoma in a murine xenograft model without recurrence. Int J Cancer 2013;132:1933-9. [PMID: 23001643 DOI: 10.1002/ijc.27860] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
157 Di Giorgio A, Sgarbura O, Rotolo S, Schena CA, Bagalà C, Inzani F, Russo A, Chiantera V, Pacelli F. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma. Ther Adv Med Oncol 2020;12:1758835920940887. [PMID: 32782488 DOI: 10.1177/1758835920940887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
158 Xie H, Jiang W, Xiao SY, Liu X. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. J Histochem Cytochem. 2013;61:148-155. [PMID: 23124118 DOI: 10.1369/0022155412468137] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
159 Shinde RS, Bhandare M, Chaudhari V, Shrikhande SV. Cutting-edge strategies for borderline resectable pancreatic cancer. Ann Gastroenterol Surg 2019;3:368-72. [PMID: 31346575 DOI: 10.1002/ags3.12254] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
160 Clark EJ, Connor S, Taylor MA, Madhavan KK, Garden OJ, Parks RW. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 2007;9:456-60. [PMID: 18345294 DOI: 10.1080/13651820701774891] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 7.4] [Reference Citation Analysis]
161 Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290-1295. [PMID: 18813308 DOI: 10.1038/sj.bjc.6604677] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 8.6] [Reference Citation Analysis]
162 Maréchal R, Demols A, Van Laethem JL. Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer. Drugs Aging 2013;30:155-65. [PMID: 23338795 DOI: 10.1007/s40266-013-0049-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
163 Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-1813. [PMID: 19273710 DOI: 10.1200/jco.2008.17.7188] [Cited by in Crossref: 704] [Cited by in F6Publishing: 378] [Article Influence: 58.7] [Reference Citation Analysis]
164 Koorstra JB, Feldmann G, Habbe N, Maitra A. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg 2008;393:561-70. [PMID: 18283486 DOI: 10.1007/s00423-008-0282-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
165 Healy MA, Krell RW, Abdelsattar ZM, McCahill LE, Kwon D, Frankel TL, Hendren S, Campbell DA Jr, Wong SL. Pancreatic Resection Results in a Statewide Surgical Collaborative. Ann Surg Oncol 2015;22:2468-74. [PMID: 25820999 DOI: 10.1245/s10434-015-4529-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
166 Rwigema JC, Heron DE, Parikh SD, Zeh HJ, Moser JA, Bahary N, Ashby K, Burton SA. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. J Gastrointest Cancer. 2012;43:70-76. [PMID: 20809393 DOI: 10.1007/s12029-010-9203-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
167 Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, Bentrem DJ. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg. 2007;11:1460-1467; discussion 1467-1469. [PMID: 17846854 DOI: 10.1007/s11605-007-0263-3] [Cited by in Crossref: 111] [Cited by in F6Publishing: 96] [Article Influence: 7.9] [Reference Citation Analysis]
168 Wu L, Guo W, Li Y, Cheng T, Yao Y, Zhang Y, Liu B, Zhong M, Li S, Deng X, Zhu W. [Value of endoscopic ultrasound-guided fine needle aspiration in pretest prediction and diagnosis of pancreatic ductal adenocarcinoma]. Nan Fang Yi Ke Da Xue Xue Bao. 2018;38:1171-1178. [PMID: 30377133 DOI: 10.3969/j.issn.1673-4254.2018.10.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
169 Prenzel KL, Warnecke-Eberz U, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Drebber U, Hoelscher AH, Schneider PM. Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World J Gastroenterol 2006;12:437-42. [PMID: 16489645 DOI: 10.3748/wjg.v12.i3.437] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
170 Holcomb BK, Yip-Schneider MT, Waters JA, Beane JD, Crooks PA, Schmidt CM. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. J Gastrointest Surg 2012;16:1333-40. [PMID: 22618517 DOI: 10.1007/s11605-012-1913-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
171 Jamiyan T, Shiraki T, Kurata Y, Ichinose M, Kubota K, Imai Y. Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma. World J Surg Oncol 2020;18:137. [PMID: 32571348 DOI: 10.1186/s12957-020-01900-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
172 Shi H, Li J, Fu D. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. J Cancer Res Clin Oncol 2016;142:1137-61. [PMID: 26250876 DOI: 10.1007/s00432-015-2024-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
173 Bouchart C, Navez J, Closset J, Hendlisz A, Van Gestel D, Moretti L, Van Laethem JL. Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard? Ther Adv Med Oncol 2020;12:1758835920936093. [PMID: 32684987 DOI: 10.1177/1758835920936093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
174 Russ AJ, Weber SM, Rettammel RJ, Mahvi DM, Rikkers LF, Cho CS. Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. Ann Surg Oncol. 2010;17:371-376. [PMID: 19851808 DOI: 10.1245/s10434-009-0759-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
175 Embuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio-Donahue CA. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005;4:548-54. [PMID: 15846069 DOI: 10.4161/cbt.4.5.1663] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 5.9] [Reference Citation Analysis]
176 Stillström D, Nilsson H, Jesse M, Peterhans M, Jonas E, Freedman J. A new technique for minimally invasive irreversible electroporation of tumors in the head and body of the pancreas. Surg Endosc 2017;31:1982-5. [PMID: 27572065 DOI: 10.1007/s00464-016-5173-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
177 Francis IR. Pancreatic adenocarcinoma: diagnosis and staging using multidetector-row computed tomography (MDCT) and magnetic resonance imaging (MRI). Cancer Imaging. 2007;7 Spec No A:S160-S165. [PMID: 17921087 DOI: 10.1102/1470-7330.2007.9010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
178 Lee JH, Kang CM, Bang SM, Choi JY, Seong JS, Hwang HK, Choi SH, Lee WJ. The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement. Medicine (Baltimore) 2015;94:e1233. [PMID: 26252282 DOI: 10.1097/MD.0000000000001233] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
179 Ballarin R, Spaggiari M, Cautero N, De Ruvo N, Montalti R, Longo C, Pecchi A, Giacobazzi P, De Marco G, D’Amico G. Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol. 2011;17:4747-4756. [PMID: 22147975 DOI: 10.3748/wjg.v17.i43.4747] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
180 Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spigel DR, Lane CM, Hainsworth JD, Burris HA 3rd. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. Cancer Biol Ther 2013;14:340-6. [PMID: 23358470 DOI: 10.4161/cbt.23625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
181 Chen S, Chen JZ, Zhan Q, Deng XX, Shen BY, Peng CH, Li HW. Robot-assisted laparoscopic versus open pancreaticoduodenectomy: a prospective, matched, mid-term follow-up study. Surg Endosc. 2015;29:3698-3711. [PMID: 25761559 DOI: 10.1007/s00464-015-4140-y] [Cited by in Crossref: 105] [Cited by in F6Publishing: 80] [Article Influence: 17.5] [Reference Citation Analysis]
182 Bruns H, Rahbari NN, Löffler T, Diener MK, Seiler CM, Glanemann M, Butturini G, Schuhmacher C, Rossion I, Büchler MW, Junghans T; DISPACT Trial group. Perioperative management in distal pancreatectomy: results of a survey in 23 European participating centres of the DISPACT trial and a review of literature. Trials 2009;10:58. [PMID: 19630998 DOI: 10.1186/1745-6215-10-58] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
183 Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J, Vollmer CM. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2013;15:49-60. [PMID: 23216779 DOI: 10.1111/j.1477-2574.2012.00571.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 8.0] [Reference Citation Analysis]
184 Ciernikova S, Earl J, García Bermejo ML, Stevurkova V, Carrato A, Smolkova B. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance? Int J Mol Sci 2020;21:E4091. [PMID: 32521716 DOI: 10.3390/ijms21114091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
185 Okubo S, Kojima M, Matsuda Y, Hioki M, Shimizu Y, Toyama H, Morinaga S, Gotohda N, Uesaka K, Ishii G, Mino-Kenudson M, Takahashi S. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Sci Rep 2019;9:17145. [PMID: 31748528 DOI: 10.1038/s41598-019-53801-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
186 Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328-335. [PMID: 21217520 DOI: 10.1097/sla.0b013e3181fd271c] [Cited by in Crossref: 258] [Cited by in F6Publishing: 151] [Article Influence: 25.8] [Reference Citation Analysis]
187 Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. J Clin Oncol 2018;36:2887-94. [PMID: 30106639 DOI: 10.1200/JCO.2017.77.6658] [Cited by in Crossref: 55] [Cited by in F6Publishing: 29] [Article Influence: 18.3] [Reference Citation Analysis]
188 Stauffer JA, Bridges MD, Turan N, Nguyen JH, Martin JK. Aberrant right hepatic arterial anatomy and pancreaticoduodenectomy: recognition, prevalence and management. HPB (Oxford). 2009;11:161-165. [PMID: 19590642 DOI: 10.1111/j.1477-2574.2009.00037.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
189 Shakri AR, Zhong TJ, Ma W, Coker C, Kim S, Calluori S, Scholze H, Szabolcs M, Caffrey T, Grandgenett PM, Hollingsworth MA, Tanji K, Kluger MD, Miller G, Biswas AK, Acharyya S. Upregulation of ZIP14 and Altered Zinc Homeostasis in Muscles in Pancreatic Cancer Cachexia. Cancers (Basel) 2019;12:E3. [PMID: 31861290 DOI: 10.3390/cancers12010003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
190 Amin S, Lucas AL, Frucht H. Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis. Pancreas. 2013;42:249-253. [PMID: 22836862 DOI: 10.1097/mpa.0b013e31825f3af4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
191 John BJ, Naik P, Ironside A, Davidson BR, Fusai G, Gillmore R, Watkins J, Rahman SH. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival. HPB (Oxford) 2013;15:674-80. [PMID: 23458477 DOI: 10.1111/hpb.12019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
192 Brasoveanu V, Barbu I, Ichim F, Balescu I, Bacalbasa N. Distal Pancreatectomy En Bloc With Splenectomy, Celiac Axis and Portal Vein Resection Followed by Arterial Reconstruction Using a Cadaveric Graft - A Case Report and Literature Review. In Vivo 2020;34:1521-5. [PMID: 32354957 DOI: 10.21873/invivo.11940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Tamburrino D, Partelli S, Crippa S, Manzoni A, Maurizi A, Falconi M. Selection criteria in resectable pancreatic cancer: a biological and morphological approach. World J Gastroenterol 2014;20:11210-5. [PMID: 25170205 DOI: 10.3748/wjg.v20.i32.11210] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
194 Qiu M, Qiu H, Jin Y, Wei X, Zhou Y, Wang Z, Wang D, Ren C, Luo H, Wang F, Zhang D, Wang F, Li Y, Yang D, Xu R. Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value. J Cancer 2016;7:694-701. [PMID: 27076851 DOI: 10.7150/jca.14185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
195 Ishizaki H, Manuel ER, Song GY, Srivastava T, Sun S, Diamond DJ, Ellenhorn JD. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model. Cancer Immunol Immunother. 2011;60:99-109. [PMID: 20960189 DOI: 10.1007/s00262-010-0923-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
196 Rohan VS, Hsu JT, Liu KH, Yeh CN, Yeh TS, Jan YY, Hwang TL. Long-term results and prognostic factors in resected pancreatic body and tail adenocarcinomas. J Gastrointest Cancer 2013;44:89-93. [PMID: 23076797 DOI: 10.1007/s12029-012-9448-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
197 Mao Z, Ma X, Fan X, Cui L, Zhu T, Qu J, Zhang J, Wang X. Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction. Tumour Biol 2014;35:10185-93. [PMID: 25027401 DOI: 10.1007/s13277-014-2315-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
198 Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, D'Ambra M, Guido A, Morselli-Labate AM, Minni F. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets. J Gastrointest Surg. 2015;19:1802-1812. [PMID: 26224039 DOI: 10.1007/s11605-015-2890-4] [Cited by in Crossref: 95] [Cited by in F6Publishing: 70] [Article Influence: 15.8] [Reference Citation Analysis]
199 Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009;11:18-24. [PMID: 19590619 DOI: 10.1111/j.1477-2574.2008.00013.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 108] [Article Influence: 12.6] [Reference Citation Analysis]
200 Gilbert JW, Wolpin B, Clancy T, Wang J, Mamon H, Shinagare AB, Jagannathan J, Rosenthal M. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017;28:2067-2076. [PMID: 28407088 DOI: 10.1093/annonc/mdx180] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
201 Yokoyama Y, Nimura Y, Nagino M. Advances in the treatment of pancreatic cancer: limitations of surgery and evaluation of new therapeutic strategies. Surg Today. 2009;39:466-475. [PMID: 19468801 DOI: 10.1007/s00595-008-3904-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
202 Hirakawa T, Yashiro M, Doi Y, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Kimura K, Amano R, Hirakawa K. Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia. PLoS One 2016;11:e0159912. [PMID: 27487118 DOI: 10.1371/journal.pone.0159912] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
203 Murphy SJ, Hart SN, Lima JF, Kipp BR, Klebig M, Winters JL, Szabo C, Zhang L, Eckloff BW, Petersen GM. Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology. 2013;145:1098-1109.e1. [PMID: 23912084 DOI: 10.1053/j.gastro.2013.07.049] [Cited by in Crossref: 108] [Cited by in F6Publishing: 98] [Article Influence: 13.5] [Reference Citation Analysis]
204 Ostapoff KT, Gabriel E, Attwood K, Kuvshinoff BW, Nurkin SJ, Hochwald SN. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma? HPB (Oxford) 2017;19:587-94. [PMID: 28433254 DOI: 10.1016/j.hpb.2017.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
205 Åkerberg D, Ansari D, Andersson R. Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas. World J Gastroenterol 2016;22:6424-33. [PMID: 27605878 DOI: 10.3748/wjg.v22.i28.6424] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
206 Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg 2005;390:94-103. [PMID: 15578211 DOI: 10.1007/s00423-004-0476-9] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
207 Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, Schmidt CM, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3:92ra66. [PMID: 21775669 DOI: 10.1126/scitranslmed.3002543] [Cited by in Crossref: 544] [Cited by in F6Publishing: 448] [Article Influence: 60.4] [Reference Citation Analysis]
208 Nguyen T. Standard vs. Radical Pancreaticoduodenectomy for Periampullary Adenocarcinoma, A Prospective, Randomized Trial Evaluating Quality of Life in Pancreaticoduodenectomy Survivors. Journal of Gastrointestinal Surgery 2003;7:1-11. [DOI: 10.1016/s1091-255x(02)00187-7] [Cited by in Crossref: 99] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
209 Perez A, Saltzman JR, Carr-Locke DL, Brooks DC, Osteen RT, Zinner MJ, Ashley SW, Whang EE. Benign nonampullary duodenal neoplasms. J Gastrointest Surg. 2003;7:536-541. [PMID: 12763412 DOI: 10.1016/s1091-255x(02)00146-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
210 Fristrup CW, Mortensen MB, Pless T, Durup J, Ainsworth A, Hovendal C, Nielsen HO. Combined endoscopic and laparoscopic ultrasound as preoperative assessment of patients with pancreatic cancer. HPB (Oxford) 2006;8:57-60. [PMID: 18333240 DOI: 10.1080/13651820500465972] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
211 Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88-95. [PMID: 19111249 DOI: 10.1016/s1470-2045(08)70337-1.] [Reference Citation Analysis]
212 Uddin MH, Al-Hallak MN, Philip PA, Mohammad RM, Viola N, Wagner KU, Azmi AS. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Cancers (Basel) 2021;13:2777. [PMID: 34204940 DOI: 10.3390/cancers13112777] [Reference Citation Analysis]
213 Kang CM, Kim DH, Choi GH, Kim KS, Choi JS, Lee WJ. Detrimental effect of postoperative complications on oncologic efficacy of R0 pancreatectomy in ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2009;13:907-14. [PMID: 19224295 DOI: 10.1007/s11605-009-0823-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
214 de Jong MC, Li F, Cameron JL, Wolfgang CL, Edil BH, Herman JM, Choti MA, Eckhauser F, Hirose K, Schulick RD, Pawlik TM. Re-evaluating the impact of tumor size on survival following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol 2011;103:656-62. [PMID: 21283994 DOI: 10.1002/jso.21883] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
215 Mian OY, Ram AN, Tuli R, Herman JM. Management options in locally advanced pancreatic cancer. Curr Oncol Rep 2014;16:388. [PMID: 24740136 DOI: 10.1007/s11912-014-0388-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
216 Wang C, Sun Y, Wu H, Yu S, Zhang L, Meng Y, Liu M, Yang H, Liu P, Mao X, Lu Z, Chen J. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 2015;36:9447-56. [PMID: 26124009 DOI: 10.1007/s13277-015-3690-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
217 Tzanakakis GN, Krambovitis E, Tsatsakis AM, Vezeridis MP. The preventive effect of ketoconazole on experimental metastasis from a human pancreatic carcinoma may be related to its effect on prostaglandin synthesis. Int J Gastrointest Cancer 2002;32:23-30. [PMID: 12630766 DOI: 10.1385/IJGC:32:1:23] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
218 Nolen BM, Lokshin AE. -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid. Int J Biol Markers 2011;26:141-52. [PMID: 21928247 DOI: 10.5301/JBM.2011.8613] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
219 Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol. 2011;24:1237-1247. [PMID: 21552209 DOI: 10.1038/modpathol.2011.74] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
220 Holyoake DL, Robinson M, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Patel N, Partridge M, Mukherjee S, Hawkins MA. Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. Radiother Oncol 2016;121:86-91. [PMID: 27519585 DOI: 10.1016/j.radonc.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
221 Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328-335. [PMID: 21217520 DOI: 10.1097/sla.0b013e3181fd271c.a] [Reference Citation Analysis]
222 Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. In Vivo 2018;32:1533-40. [PMID: 30348713 DOI: 10.21873/invivo.11411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
223 Lin C, Verma V, Lazenby A, Ly QP, Berim LD, Schwarz JK, Madiyalakan M, Nicodemus CF, Hollingsworth MA, Meza JL, Are C, Padussis J, Grem JL. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol 2019;42:755-60. [PMID: 31513018 DOI: 10.1097/COC.0000000000000599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
224 Murakami Y, Uemura K, Sudo T, Hashimoto Y, Yuasa Y, Sueda T. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg. 2010;34:1900-1907. [PMID: 20376442 DOI: 10.1007/s00268-010-0577-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
225 Cheung TT, Poon RT, Chok KS, Chan AC, Tsang SH, Dai WC, Chan SC, Fan ST, Lo CM. Pancreaticoduodenectomy with vascular reconstruction for adenocarcinoma of the pancreas with borderline resectability. World J Gastroenterol 2014;20:17448-55. [PMID: 25516657 DOI: 10.3748/wjg.v20.i46.17448] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
226 Venkatesulu BP, Hsieh CE, Sanders KL, Krishnan S. Recent advances in radiation therapy of pancreatic cancer. F1000Res 2018;7:F1000 Faculty Rev-1931. [PMID: 30613390 DOI: 10.12688/f1000research.16272.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
227 Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther 2016;9:7459-67. [PMID: 28003762 DOI: 10.2147/OTT.S100510] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
228 Lee SJ, Kim JH, Kim SY, Won HJ, Shin YM, Kim PN. Percutaneous Radiofrequency Ablation for Metachronous Hepatic Metastases after Curative Resection of Pancreatic Adenocarcinoma. Korean J Radiol 2020;21:316-24. [PMID: 32090524 DOI: 10.3348/kjr.2019.0647] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
229 Clark E, Connor S, Taylor MA, Hendry CL, Madhavan KK, Garden OJ, Parks RW. Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 2007;9:472-7. [PMID: 18345298 DOI: 10.1080/13651820701769693] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
230 Schönleben F, Qiu W, Allendorf JD, Chabot JA, Remotti HE, Su GH. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg. 2009;13:1510-1516. [PMID: 19440799 DOI: 10.1007/s11605-009-0917-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
231 Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418-425. [PMID: 18087285 DOI: 10.1038/sj.bjc.6604129] [Cited by in Crossref: 240] [Cited by in F6Publishing: 217] [Article Influence: 17.1] [Reference Citation Analysis]
232 van Heek NT, Kuhlmann KF, Scholten RJ, de Castro SM, Busch OR, van Gulik TM, Obertop H, Gouma DJ. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg. 2005;242:781-788. [PMID: 16327488 DOI: 10.1097/01.sla.0000188462.00249.36] [Cited by in Crossref: 258] [Cited by in F6Publishing: 206] [Article Influence: 17.2] [Reference Citation Analysis]
233 Delpero JR, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Autret A, Turrini O, Monges-Ranchin G. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford). 2014;16:20-33. [PMID: 23464850 DOI: 10.1111/hpb.12061] [Cited by in Crossref: 105] [Cited by in F6Publishing: 77] [Article Influence: 13.1] [Reference Citation Analysis]
234 Robinson PA. The role of MRI in pancreatic cancer. Eur Radiol 2002;12:267-9. [PMID: 11870421 DOI: 10.1007/s00330-001-1148-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
235 Riall TS, Cameron JL, Lillemoe KD, Campbell KA, Sauter PK, Coleman J, Abrams RA, Laheru D, Hruban RH, Yeo CJ. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg. 2005;9:1191-1204; discussion 1204-1206. [PMID: 16332474 DOI: 10.1016/j.gassur.2005.08.034] [Cited by in Crossref: 164] [Cited by in F6Publishing: 126] [Article Influence: 10.9] [Reference Citation Analysis]
236 Parlak C, Topkan E, Onal C, Reyhan M, Selek U. Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiat Oncol 2012;7:37. [PMID: 22429939 DOI: 10.1186/1748-717X-7-37] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
237 Polistina F, Di Natale G, Bonciarelli G, Ambrosino G, Frego M. Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol 2014;20:9374-83. [PMID: 25071332 DOI: 10.3748/wjg.v20.i28.9374] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
238 Porembka MR, Hawkins WG, Linehan DC, Gao F, Ma C, Brunt EM, Strasberg SM. Radiologic and intraoperative detection of need for mesenteric vein resection in patients with adenocarcinoma of the head of the pancreas. HPB (Oxford) 2011;13:633-42. [PMID: 21843264 DOI: 10.1111/j.1477-2574.2011.00343.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
239 Botsis T, Anagnostou VK, Hartvigsen G, Hripcsak G, Weng C. Modeling prognostic factors in resectable pancreatic adenocarcinomas. Cancer Inform 2010;7:281-91. [PMID: 20508721 DOI: 10.4137/cin.s3835] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
240 Wang X, Deng Y, Mao Z, Ma X, Fan X, Cui L, Qu J, Xie D, Zhang J. CCN1 promotes tumorigenicity through Rac1/Akt/NF-κB signaling pathway in pancreatic cancer. Tumour Biol 2012;33:1745-58. [PMID: 22752926 DOI: 10.1007/s13277-012-0434-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
241 Bae JS, Kim JH, Joo I, Chang W, Han JK. MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer. Eur Radiol 2019;29:3714-24. [PMID: 30899975 DOI: 10.1007/s00330-019-06140-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
242 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 100] [Article Influence: 11.1] [Reference Citation Analysis]
243 Fitzmaurice C, Seiler CM, Büchler MW, Diener MK. [Survival, mortality and quality of life after pylorus-preserving or classical Whipple operation. A systematic review with meta-analysis]. Chirurg 2010;81:454-71. [PMID: 20020091 DOI: 10.1007/s00104-009-1829-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
244 Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N, Rezaee N, Herman J, Zheng L, Laheru D, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL, Weiss MJ. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol 2014;21:2873-81. [PMID: 24770680 DOI: 10.1245/s10434-014-3722-6] [Cited by in Crossref: 114] [Cited by in F6Publishing: 86] [Article Influence: 16.3] [Reference Citation Analysis]
245 Eisenberg DP, Adusumilli PS, Hendershott KJ, Yu Z, Mullerad M, Chan MK, Chou TC, Fong Y. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg. 2005;9:1068-1077. [PMID: 16269377 DOI: 10.1016/j.gassur.2005.06.024] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
246 Fischer LK, Katz MH, Lee SM, Liu L, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Roland CL, Fleming JB, Estrella J, Rashid A, Wang H. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology 2016;68:210-20. [PMID: 25945396 DOI: 10.1111/his.12732] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
247 Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford). 2008;10:371-376. [PMID: 18982154 DOI: 10.1080/13651820802291233] [Cited by in Crossref: 115] [Cited by in F6Publishing: 93] [Article Influence: 10.5] [Reference Citation Analysis]
248 Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J, Van Laethem JL. New challenges in perioperative management of pancreatic cancer. World J Gastroenterol. 2015;21:2281-2293. [PMID: 25741134 DOI: 10.3748/wjg.v21.i8.2281] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
249 Riall TS, Eschbach KA, Townsend CM, Nealon WH, Freeman JL, Goodwin JS. Trends and disparities in regionalization of pancreatic resection. J Gastrointest Surg. 2007;11:1242-1251. [PMID: 17694419 DOI: 10.1007/s11605-007-0245-5] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
250 Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, Zavada J, Yoshida M, Yamada K, Koyama T, Kanai Y. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer 2010;103:1057-65. [PMID: 20736942 DOI: 10.1038/sj.bjc.6605854] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 6.4] [Reference Citation Analysis]
251 Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection. J Gastrointest Surg. 2006;10:1106-1115. [PMID: 16966029 DOI: 10.1016/j.gassur.2006.04.002] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 7.9] [Reference Citation Analysis]
252 Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, Sueda T. Postoperative adjuvant chemotherapy improves survival after surgical resection for pancreatic carcinoma. J Gastrointest Surg 2008;12:534-41. [PMID: 18026816 DOI: 10.1007/s11605-007-0407-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
253 Khaled YS, Ammori BJ, Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J Immunol Res. 2014;2014:879897. [PMID: 24741628 DOI: 10.1155/2014/879897] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 10.4] [Reference Citation Analysis]
254 Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA. Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med 2013;5:26. [PMID: 23673020 DOI: 10.1186/gm430] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
255 Mayo SC, Gilson MM, Herman JM, Cameron JL, Nathan H, Edil BH, Choti MA, Schulick RD, Wolfgang CL, Pawlik TM. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214:33-45. [PMID: 22055585 DOI: 10.1016/j.jamcollsurg.2011.09.022] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 9.8] [Reference Citation Analysis]
256 Lu F, Soares KC, He J, Javed AA, Cameron JL, Rezaee N, Pawlik TM, Wolfgang CL, Weiss MJ. Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival. Hepatobiliary Surg Nutr 2017;6:144-53. [PMID: 28652997 DOI: 10.21037/hbsn.2016.08.06] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
257 Meng X, Liu P, Wu Y, Liu X, Huang Y, Yu B, Han J, Jin H, Tan X. Integrin beta 4 (ITGB4) and its tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and regulate the MEK1-ERK1/2 signaling pathway. Bosn J Basic Med Sci 2020;20:106-16. [PMID: 31242404 DOI: 10.17305/bjbms.2019.4255] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
258 Tsvetkova EV, Asmis TR. Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here? Curr Oncol. 2014;21:e650-e657. [PMID: 25089113 DOI: 10.3747/co.21.2006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
259 Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, Griffith M, Omura N, Medghalchi S, Kuhajda F. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18:2380-2385. [PMID: 19723916 DOI: 10.1158/1055-9965.epi-09-0144] [Cited by in Crossref: 60] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
260 Di Marco M, Grassi E, Durante S, Vecchiarelli S, Palloni A, Macchini M, Casadei R, Ricci C, Panzacchi R, Santini D, Biasco G. State of the art biological therapies in pancreatic cancer. World J Gastrointest Oncol 2016;8:55-66. [PMID: 26798437 DOI: 10.4251/wjgo.v8.i1.55] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
261 Sakin A, Sahin S, Sakin A, Atci MM, Arici S, Yasar N, Demir C, Geredeli C, Cihan S. Factors affecting survival in operated pancreatic cancer: Does tumor localization have a significant effect on treatment outcomes? North Clin Istanb 2020;7:487-93. [PMID: 33163885 DOI: 10.14744/nci.2020.09735] [Reference Citation Analysis]
262 Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of pancreatic intraepithelial neoplasia in the pancreatic transection margin does not influence outcome in patients with R0 resected pancreatic cancer. Ann Surg Oncol 2011;18:3493-9. [PMID: 21537863 DOI: 10.1245/s10434-011-1745-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
263 Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, Matsunaga K, Maeda A. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:977-985. [PMID: 22411488 DOI: 10.1007/s11605-012-1859-9] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
264 Gonzalo-Marin J, Vila JJ, Perez-Miranda M. Role of endoscopic ultrasound in the diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014;6:360-368. [PMID: 25232461 DOI: 10.4251/wjgo.v6.i9.360] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
265 Oliveira-Cunha M, Malde DJ, Aldouri A, Morris-Stiff G, Menon KV, Smith AM. Results of pancreatic surgery in the elderly: is age a barrier? HPB (Oxford). 2013;15:24-30. [PMID: 23216776 DOI: 10.1111/j.1477-2574.2012.00549.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
266 Liao WC, Wang HP, Huang HY, Wu MS, Chiang H, Tien YW, Lin YL, Lin JT. CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma. Clin Transl Gastroenterol 2012;3:e22. [PMID: 23238349 DOI: 10.1038/ctg.2012.18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
267 Wang T, Wentz SC, Ausborn NL, Washington MK, Merchant N, Zhao Z, Shyr Y, Chakravarthy AB, Xia F. Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma. Pancreas 2013;42:977-82. [PMID: 23851432 DOI: 10.1097/MPA.0b013e318287885c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
268 Khosrawipour T, Khosrawipour V, Giger-Pabst U. Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS One. 2017;12:e0186709. [PMID: 29049340 DOI: 10.1371/journal.pone.0186709] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
269 Biondetti P, Fumarola EM, Ierardi AM, Carrafiello G. Bleeding complications after pancreatic surgery: interventional radiology management. Gland Surg 2019;8:150-63. [PMID: 31183325 DOI: 10.21037/gs.2019.01.06] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
270 Lewis AM, Ough M, Hinkhouse MM, Tsao MS, Oberley LW, Cullen JJ. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 2005;43:215-24. [PMID: 16003741 DOI: 10.1002/mc.20107] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
271 Baker MS, Knuth JL, DeWitt J, LeBlanc J, Cramer H, Howard TJ, Schmidt CM, Lillemoe KD, Pitt HA. Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology. J Gastrointest Surg. 2008;12:450-456. [PMID: 18157720 DOI: 10.1007/s11605-007-0219-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
272 Dholakia AS, Hacker-Prietz A, Wild AT, Raman SP, Wood LD, Huang P, Laheru DA, Zheng L, De Jesus-Acosta A, Le DT, Schulick R, Edil B, Ellsworth S, Pawlik TM, Iacobuzio-Donahue CA, Hruban RH, Cameron JL, Fishman EK, Wolfgang CL, Herman JM. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumour-vessel relationships. J Radiat Oncol. 2013;2:413-425. [PMID: 25755849 DOI: 10.1007/s13566-013-0115-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
273 Lockney NA, Zhang M, Lu Y, Sopha SC, Washington MK, Merchant N, Zhao Z, Shyr Y, Chakravarthy AB, Xia F. Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarcinoma. J Gastrointest Cancer 2015;46:390-8. [PMID: 26385349 DOI: 10.1007/s12029-015-9764-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
274 Wiltberger G, Bucher JN, Krenzien F, Benzing C, Atanasov G, Schmelzle M, Hau HM, Bartels M. Extended resection in pancreatic metastases: feasibility, frequency, and long-term outcome: a retrospective analysis. BMC Surg. 2015;15:126. [PMID: 26772176 DOI: 10.1186/s12893-015-0114-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
275 Gaedcke J, Gunawan B, Grade M, Szöke R, Liersch T, Becker H, Ghadimi BM. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg. 2010;395:451-458. [PMID: 19418067 DOI: 10.1007/s00423-009-0494-8] [Cited by in Crossref: 97] [Cited by in F6Publishing: 73] [Article Influence: 8.1] [Reference Citation Analysis]
276 Tonini G, Vincenzi B, Santini D, Scarpa S, Vasaturo T, Malacrino C, Coppola R, Magistrelli P, Borzomati D, Baldi A, Antinori A, Caricato M, Nuzzo G, Picciocchi A. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer 2005;92:2225-32. [PMID: 15928668 DOI: 10.1038/sj.bjc.6602632] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
277 Chandrabalan VV, McMillan DC, Carter R, Kinsella J, McKay CJ, Carter CR, Dickson EJ. Pre-operative cardiopulmonary exercise testing predicts adverse post-operative events and non-progression to adjuvant therapy after major pancreatic surgery. HPB (Oxford) 2013;15:899-907. [PMID: 23458160 DOI: 10.1111/hpb.12060] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
278 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
279 Stutchfield BM, Joseph S, Duckworth AD, Garden OJ, Parks RW. Distal pancreatectomy: what is the standard for laparoscopic surgery? HPB (Oxford) 2009;11:210-4. [PMID: 19590649 DOI: 10.1111/j.1477-2574.2009.00008.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
280 He YC, Peng W, Qiao JG, Cao J, Chen JW. Relationship between nuclear morphometry, DNA content and resectability of pancreatic cancer. World J Gastroenterol 2003;9:1863-5. [PMID: 12918140 DOI: 10.3748/wjg.v9.i8.1863] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
281 Dedania N, Agrawal N, Winter JM, Koniaris LG, Rosato EL, Sauter PK, Leiby B, Pequignot E, Yeo CJ, Lavu H. Splenic vein thrombosis is associated with an increase in pancreas-specific complications and reduced survival in patients undergoing distal pancreatectomy for pancreatic exocrine cancer. J Gastrointest Surg. 2013;17:1392-1398. [PMID: 23797883 DOI: 10.1007/s11605-013-2260-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
282 Raigani S, Ammori J, Kim J, Hardacre JM. Trends in the treatment of resectable pancreatic adenocarcinoma. J Gastrointest Surg 2014;18:113-23. [PMID: 24002769 DOI: 10.1007/s11605-013-2335-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
283 Cooper AB, Tzeng CW, Katz MH. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol. 2013;14:293-310. [PMID: 23793524 DOI: 10.1007/s11864-013-0244-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
284 Muhammad SU, Azam F, Zuzana S. Primary pancreatic leiomyosarcoma: a case report. Cases J 2008;1:280. [PMID: 18957130 DOI: 10.1186/1757-1626-1-280] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
285 Yu IS, Cheung WY. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Can J Gastroenterol Hepatol 2018;2018:1863535. [PMID: 29623263 DOI: 10.1155/2018/1863535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
286 Taboada AGM, Lominchar PL, Roman LM, García-Alfonso P, Martin AJM, Rodriguez JAB, Pascual JMA. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. Ann Hepatobiliary Pancreat Surg 2021;25:179-91. [PMID: 34053920 DOI: 10.14701/ahbps.2021.25.2.179] [Reference Citation Analysis]
287 Liang S, Hameed U, Jayaraman S. Laparoscopic pancreatectomy: indications and outcomes. World J Gastroenterol. 2014;20:14246-14254. [PMID: 25339811 DOI: 10.3748/wjg.v20.i39.14246] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
288 Clark EJ, Taylor MA, Connor S, O'Neill R, Brennan MF, Garden OJ, Parks RW. Validation of a prognostic nomogram in patients undergoing resection for pancreatic ductal adenocarcinoma in a UK tertiary referral centre. HPB (Oxford) 2008;10:501-5. [PMID: 19088940 DOI: 10.1080/13651820802356606] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
289 van Heek NT, Clayton SJ, Sturm PD, Walker J, Gouma DJ, Noorduyn LA, Offerhaus GJ, Fox JC. Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses. J Clin Pathol 2005;58:1315-20. [PMID: 16311354 DOI: 10.1136/jcp.2004.022707] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
290 Ouaissi M, Hubert C, Verhelst R, Astarci P, Sempoux C, Jouret-Mourin A, Loundou A, Gigot JF; Multidisciplary HPB Group of Center of Cancer. Vascular reconstruction during pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure. World J Surg. 2010;34:2648-2661. [PMID: 20607257 DOI: 10.1007/s00268-010-0699-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
291 Kelly KJ, Winslow E, Kooby D, Lad NL, Parikh AA, Scoggins CR, Ahmad S, Martin RC, Maithel SK, Kim HJ, Merchant NB, Cho CS, Weber SM. Vein Involvement During Pancreaticoduodenectomy: Is There a Need for Redefinition of “Borderline Resectable Disease”? J Gastrointest Surg 2013;17:1209-17. [DOI: 10.1007/s11605-013-2178-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
292 Xia BT, Habib DA, Dhar VK, Levinsky NC, Kim Y, Hanseman DJ, Sutton JM, Wilson GC, Smith M, Choe KA, Sussman JJ, Ahmad SA, Abbott DE. Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach. Ann Surg Oncol 2016;23:4156-64. [PMID: 27459987 DOI: 10.1245/s10434-016-5457-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
293 Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006;10:1199-210; discussion 1210-1. [PMID: 17114007 DOI: 10.1016/j.gassur.2006.08.018] [Cited by in Crossref: 1061] [Cited by in F6Publishing: 868] [Article Influence: 75.8] [Reference Citation Analysis]
294 Mahipal A, Frakes J, Hoffe S, Kim R. Management of borderline resectable pancreatic cancer. World J Gastrointest Oncol. 2015;7:241-249. [PMID: 26483878 DOI: 10.4251/wjgo.v7.i10.241] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
295 Stark AP, Sacks GD, Rochefort MM, Donahue TR, Reber HA, Tomlinson JS, Dawson DW, Eibl G, Hines OJ. Long-term survival in patients with pancreatic ductal adenocarcinoma. Surgery 2016;159:1520-7. [PMID: 26847803 DOI: 10.1016/j.surg.2015.12.024] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
296 Han SL, Zhang WJ, Zheng XF, Shen X, Zeng QQ, Ke QH. Radical resection and outcome for malignant tumors of the pancreatic body and tail. World J Gastroenterol 2009;15:5346-51. [PMID: 19908345 DOI: 10.3748/wjg.15.5346] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
297 Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27:358-367. [PMID: 26361405 DOI: 10.3978/j.issn.1000-9604.2015.05.02] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
298 Zhang C, Yang G, Ling Y, Chen G, Zhou T. The early diagnosis of pancreatic cancer and diabetes: what's the relationship? J Gastrointest Oncol. 2014;5:481-488. [PMID: 25436129 DOI: 10.3978/j.issn.2078-6891.2014.055] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
299 Knaebel HP, Märten A, Schmidt J, Hoffmann K, Seiler C, Lindel K, Schmitz-Winnenthal H, Fritz S, Herrmann T, Goldschmidt H, Krempien R, Mansmann U, Debus J, Diehl V, Büchler MW. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]. BMC Cancer 2005;5:37. [PMID: 15826316 DOI: 10.1186/1471-2407-5-37] [Cited by in Crossref: 67] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
300 Zhang F, Zhong W, Li H, Huang K, Yu M, Liu Y. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer. Front Cell Dev Biol 2021;9:665265. [PMID: 34124046 DOI: 10.3389/fcell.2021.665265] [Reference Citation Analysis]
301 Khanna A, Walker GR, Livingstone AS, Arheart KL, Rocha-Lima C, Koniaris LG. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg 2006;10:689-97. [PMID: 16713541 DOI: 10.1016/j.gassur.2005.11.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
302 Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511-518. [PMID: 16627216 DOI: 10.1016/j.gassur.2005.09.016] [Cited by in Crossref: 215] [Cited by in F6Publishing: 166] [Article Influence: 14.3] [Reference Citation Analysis]
303 Castellanos E, Berlin J, Cardin DB. Current treatment options for pancreatic carcinoma. Curr Oncol Rep 2011;13:195-205. [PMID: 21491194 DOI: 10.1007/s11912-011-0164-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
304 Cannon RM, LeGrand R, Chagpar RB, Ahmad SA, McClaine R, Kim HJ, Rupp C, Cho CS, Brinkman A, Weber S. Multi-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resection. HPB (Oxford). 2012;14:228-235. [PMID: 22404260 DOI: 10.1111/j.1477-2574.2011.00432.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
305 Dabizzi E, Assef MS, Raimondo M. Diagnostic management of pancreatic cancer. Cancers (Basel) 2011;3:494-509. [PMID: 24212626 DOI: 10.3390/cancers3010494] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
306 Ronnekleiv-Kelly SM, Greenblatt DY, Lin CP, Kelly KJ, Cho CS, Winslow ER, Weber SM. Impact of cardiac comorbidity on early outcomes after pancreatic resection. J Gastrointest Surg 2014;18:512-22. [PMID: 24277570 DOI: 10.1007/s11605-013-2399-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
307 Newhook TE, Blais EM, Lindberg JM, Adair SJ, Xin W, Lee JK, Papin JA, Parsons JT, Bauer TW. A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest. PLoS One 2014;9:e105631. [PMID: 25180633 DOI: 10.1371/journal.pone.0105631] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
308 Mirkin KA, Greenleaf EK, Hollenbeak CS, Wong J. Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resected pancreatic cancer. Surg Endosc 2018;32:2387-96. [PMID: 29101568 DOI: 10.1007/s00464-017-5937-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
309 Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene 2013;32:5253-60. [PMID: 23416985 DOI: 10.1038/onc.2013.29] [Cited by in Crossref: 120] [Cited by in F6Publishing: 91] [Article Influence: 15.0] [Reference Citation Analysis]
310 Mogal H, Vermilion SA, Dodson R, Hsu FC, Howerton R, Shen P, Clark CJ. Modified Frailty Index Predicts Morbidity and Mortality After Pancreaticoduodenectomy. Ann Surg Oncol 2017;24:1714-21. [PMID: 28058551 DOI: 10.1245/s10434-016-5715-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 14.0] [Reference Citation Analysis]
311 Amr B, Shahtahmassebi G, Briggs CD, Bowles MJ, Aroori S, Stell DA. Assessment of the effect of interval from presentation to surgery on outcome in patients with peri-ampullary malignancy. HPB (Oxford) 2016;18:354-9. [PMID: 27037205 DOI: 10.1016/j.hpb.2015.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
312 Moody JS, Sawrie SM, Kozak KR, Plastaras JP, Howard G, Bonner JA. Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patients. J Gastroenterol. 2009;44:84-91. [PMID: 19159077 DOI: 10.1007/s00535-008-2280-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
313 Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol 2009;2:13. [PMID: 19291303 DOI: 10.1186/1756-8722-2-13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
314 Honda K, Srivastava S. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Biomark Med 2016;10:1197-207. [PMID: 27673558 DOI: 10.2217/bmm-2016-0209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
315 Riall TS. What is the effect of age on pancreatic resection? Adv Surg. 2009;43:233-249. [PMID: 19845182 DOI: 10.1016/j.yasu.2009.02.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
316 Lowy AM. Transgenic models of pancreatic cancer. Int J Gastrointest Cancer. 2003;33:71-78. [PMID: 12909739 DOI: 10.1385/IJGC:33:1:71] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
317 Foo WC, Rashid A, Wang H, Katz MH, Lee JE, Pisters PW, Wolff RA, Abbruzzese JL, Fleming JB, Wang H. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Hum Pathol. 2013;44:1024-1030. [PMID: 23260327 DOI: 10.1016/j.humpath.2012.09.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
318 Chang YR, Han SS, Park SJ, Lee SD, Yoo TS, Kim YK, Kim TH, Woo SM, Lee WJ, Hong EK. Surgical outcome of pancreatic cancer using radical antegrade modular pancreatosplenectomy procedure. World J Gastroenterol. 2012;18:5595-5600. [PMID: 23112553 DOI: 10.3748/wjg.v18.i39.5595] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
319 Sheikh M, Masoudi S, Bakhshandeh R, Moayyedkazemi A, Zamani F, Nikfam S, Mansouri M, Shishavan NG, Nikeghbalian S, Brennan P, Malekzadeh R, Pourshams A. Survival features, prognostic factors, and determinants of diagnosis and treatment among Iranian patients with pancreatic cancer, a prospective study. PLoS One 2020;15:e0243511. [PMID: 33275621 DOI: 10.1371/journal.pone.0243511] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Russo S, Ammori J, Eads J, Dorth J. The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol. 2016;12:669-685. [PMID: 26880384 DOI: 10.2217/fon.15.335] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
321 Kim BR, Kim JH, Ahn SJ, Joo I, Choi SY, Park SJ, Han JK. CT prediction of resectability and prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant treatment using image findings and texture analysis. Eur Radiol. 2019;29:362-372. [PMID: 29931561 DOI: 10.1007/s00330-018-5574-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
322 Koniaris LG, Staveley-O'Carroll KF, Zeh HJ, Perez E, Jin XL, Maley WR, Zabari G, Bartlett DL, Khanna A, Franceschi D, Schoeniger LO. Pancreaticoduodenectomy in the presence of superior mesenteric venous obstruction. J Gastrointest Surg 2005;9:915-21. [PMID: 16137584 DOI: 10.1016/j.gassur.2005.04.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
323 Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, Nakayama G, Sugimoto H, Koike M, Nomoto S. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. 2014;44:1692-1701. [PMID: 24114022 DOI: 10.1007/s00595-013-0752-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
324 Hatzaras I, Schmidt C, Klemanski D, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Pancreatic resection in the octogenarian: a safe option for pancreatic malignancy. J Am Coll Surg. 2011;212:373-377. [PMID: 21227721 DOI: 10.1016/j.jamcollsurg.2010.10.015] [Cited by in Crossref: 78] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
325 Hedgire SS, Mino-Kenudson M, Elmi A, Thayer S, Fernandez-del Castillo C, Harisinghani MG. Enhanced primary tumor delineation in pancreatic adenocarcinoma using ultrasmall super paramagnetic iron oxide nanoparticle-ferumoxytol: an initial experience with histopathologic correlation. Int J Nanomedicine 2014;9:1891-6. [PMID: 24790431 DOI: 10.2147/IJN.S59788] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 3.1] [Reference Citation Analysis]
326 Saka B, Balci S, Basturk O, Bagci P, Postlewait LM, Maithel S, Knight J, El-Rayes B, Kooby D, Sarmiento J, Muraki T, Oliva I, Bandyopadhyay S, Akkas G, Goodman M, Reid MD, Krasinskas A, Everett R, Adsay V. Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: ≤2, pT2: >2-≤4, pT3: >4 cm) is More Valid and Clinically Relevant. Ann Surg Oncol 2016;23:2010-8. [PMID: 26832882 DOI: 10.1245/s10434-016-5093-7] [Cited by in Crossref: 69] [Cited by in F6Publishing: 52] [Article Influence: 13.8] [Reference Citation Analysis]
327 Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88-95. [PMID: 19111249 DOI: 10.1016/s1470-2045(08)70337-1] [Cited by in Crossref: 308] [Cited by in F6Publishing: 148] [Article Influence: 25.7] [Reference Citation Analysis]
328 Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 2012;7:28. [PMID: 22385572 DOI: 10.1186/1748-717x-7-28] [Cited by in Crossref: 67] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
329 Piperdi M, McDade TP, Shim JK, Piperdi B, Kadish SP, Sullivan ME, Whalen GF, Tseng JF. A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database. HPB (Oxford) 2010;12:204-10. [PMID: 20590888 DOI: 10.1111/j.1477-2574.2009.00150.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
330 DeOliveira ML, Winter JM, Schafer M, Cunningham SC, Cameron JL, Yeo CJ, Clavien PA. Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg 2006;244:931-7; discussion 937-9. [PMID: 17122618 DOI: 10.1097/01.sla.0000246856.03918.9a] [Cited by in Crossref: 548] [Cited by in F6Publishing: 437] [Article Influence: 39.1] [Reference Citation Analysis]
331 Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246:52-60. [PMID: 17592291 DOI: 10.1097/01.sla.0000259391.84304.2b] [Cited by in Crossref: 425] [Cited by in F6Publishing: 353] [Article Influence: 30.4] [Reference Citation Analysis]
332 Bhatti I, Peacock O, Awan AK, Semeraro D, Larvin M, Hall RI. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg. 2010;34:768-775. [PMID: 20052471 DOI: 10.1007/s00268-009-0336-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
333 Bergenfeldt M, Moesgaard F, Burcharth F. Curative resection for left-sided pancreatic malignancy. HPB (Oxford) 2006;8:211-5. [PMID: 18333279 DOI: 10.1080/13651820500497165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
334 Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788-97; discussion 797-9. [PMID: 15166958 DOI: 10.1097/01.sla.0000128306.90650.aa] [Cited by in Crossref: 628] [Cited by in F6Publishing: 505] [Article Influence: 36.9] [Reference Citation Analysis]
335 Hicks CW, Tosoian JJ, Craig-Schapiro R, Valero V 3rd, Cameron JL, Eckhauser FE, Hirose K, Makary MA, Pawlik TM, Ahuja N, Weiss MJ, Wolfgang CL. Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. Am J Surg 2015;210:636-42.e1. [PMID: 26384793 DOI: 10.1016/j.amjsurg.2015.05.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
336 Masui T, Doi R, Kawaguchi Y, Sato A, Nakano K, Ito T, Anazawa T, Takaori K, Uemoto S. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. Surg Today 2016;46:1282-9. [PMID: 26860274 DOI: 10.1007/s00595-016-1310-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
337 Ashfaq A, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2014;18:1929-35. [PMID: 24916590 DOI: 10.1007/s11605-014-2566-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
338 Mauri G, Mattiuz C, Sconfienza LM, Pedicini V, Poretti D, Melchiorre F, Rossi U, Lutman FR, Montorsi M. Role of interventional radiology in the management of complications after pancreatic surgery: a pictorial review. Insights Imaging 2015;6:231-9. [PMID: 25516470 DOI: 10.1007/s13244-014-0372-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
339 Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355-66; discussion 366-8. [PMID: 12192322 DOI: 10.1097/00000658-200209000-00012] [Cited by in Crossref: 562] [Cited by in F6Publishing: 434] [Article Influence: 29.6] [Reference Citation Analysis]
340 Torphy RJ, Tignanelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, Yeh JJ. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. PLoS One 2014;9:e89474. [PMID: 24586805 DOI: 10.1371/journal.pone.0089474] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
341 Rong Y, Qin X, Jin D, Lou W, Wu L, Wang D, Wu W, Ni X, Mao Z, Kuang T. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med. 2012;12:173-180. [PMID: 21932124 DOI: 10.1007/s10238-011-0159-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
342 Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236:355-366; discussion 366-368. [PMID: 12192322 DOI: 10.1097/01.sla.0000027272.08464.0b] [Reference Citation Analysis]
343 Koti RS, Gurusamy KS, Fusai G, Davidson BR. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review. HPB (Oxford). 2010;12:155-165. [PMID: 20590882 DOI: 10.1111/j.1477-2574.2010.00157.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 7.1] [Reference Citation Analysis]
344 van Rijssen LB, Narwade P, van Huijgevoort NC, Tseng DS, van Santvoort HC, Molenaar IQ, van Laarhoven HW, van Eijck CH, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group. Prognostic value of lymph node metastases detected during surgical exploration for pancreatic or periampullary cancer: a systematic review and meta-analysis. HPB (Oxford) 2016;18:559-66. [PMID: 27346135 DOI: 10.1016/j.hpb.2016.05.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
345 Furukawa K, Uwagawa T, Haruki K, Fujiwara Y, Iida T, Shiba H, Misawa T, Ohashi T, Yanaga K. Nuclear factor κB activity correlates with the progression and prognosis of pancreatic cancer in a mouse model. Surg Today 2013;43:171-7. [PMID: 22892758 DOI: 10.1007/s00595-012-0279-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
346 Zacharias T, Jaeck D, Oussoultzoglou E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2007;11:350-356. [PMID: 17458610 DOI: 10.1007/s11605-007-0113-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
347 Nigri G, Petrucciani N, Belloni E, Lucarini A, Aurello P, D'Angelo F, di Saverio S, Fancellu A, Ramacciato G. Distal Pancreatectomy with Celiac Axis Resection: Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:1967. [PMID: 33921838 DOI: 10.3390/cancers13081967] [Reference Citation Analysis]
348 Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 2012;118:2674-2681. [PMID: 21935914 DOI: 10.1002/cncr.26553] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 9.1] [Reference Citation Analysis]
349 Majumder S, Chari ST, Ahlquist DA. Molecular detection of pancreatic neoplasia: Current status and future promise. World J Gastroenterol. 2015;21:11387-11395. [PMID: 26526068 DOI: 10.3748/wjg.v21.i40.11387] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
350 Weyhe D, Obonyo D, Uslar VN, Stricker I, Tannapfel A. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data. PLoS One 2021;16:e0248633. [PMID: 33735191 DOI: 10.1371/journal.pone.0248633] [Reference Citation Analysis]
351 Kim ER, Bae SY, Lee KH, Lee KT, Son HJ, Rhee JC, Lee JK. Is health screening beneficial for early detection and prognostic improvement in pancreatic cancer? Gut Liver. 2011;5:194-199. [PMID: 21814600 DOI: 10.5009/gnl.2011.5.2.194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
352 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
353 Hruban RH, Canto MI, Griffin C, Kern SE, Klein AP, Laheru D, Yeo CJ. Treatment of familial pancreatic cancer and its precursors. Curr Treat Options Gastroenterol 2005;8:365-75. [PMID: 16162302 DOI: 10.1007/s11938-005-0039-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
354 Matos JM, Schmidt CM, Turrini O, Agaram NP, Niedergethmann M, Saeger HD, Merchant N, Johnson CS, Lillemoe KD, Grützmann R. Pancreatic Acinar Cell Carcinoma: A Multi-institutional Study. J Gastrointest Surg 2009;13:1495-502. [DOI: 10.1007/s11605-009-0938-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
355 Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers (Basel). 2019;11. [PMID: 30965637 DOI: 10.3390/cancers11040497] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
356 Waterhouse MA, Burmeister EA, O'Connell DL, Ballard EL, Jordan SJ, Merrett ND, Goldstein D, Wyld D, Janda M, Beesley VL, Payne ME, Gooden HM, Neale RE. Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study. J Gastrointest Surg 2016;20:1471-81. [PMID: 27184672 DOI: 10.1007/s11605-016-3157-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
357 Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318-348. [PMID: 23856911 DOI: 10.3322/caac.21190] [Cited by in Crossref: 479] [Cited by in F6Publishing: 421] [Article Influence: 59.9] [Reference Citation Analysis]
358 La Torre M, Nigri G, Lo Conte A, Mazzuca F, Tierno SM, Salaj A, Marchetti P, Ziparo V, Ramacciato G. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver 2014;8:102-8. [PMID: 24516708 DOI: 10.5009/gnl.2014.8.1.102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
359 Ausborn NL, Wang T, Wentz SC, Washington MK, Merchant NB, Zhao Z, Shyr Y, Chakravarthy AB, Xia F. 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. BMC Cancer 2013;13:155. [PMID: 23530749 DOI: 10.1186/1471-2407-13-155] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
360 Tummala P, Howard T, Agarwal B. Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes. Clin Transl Gastroenterol 2013;4:e33. [PMID: 23515131 DOI: 10.1038/ctg.2013.4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
361 Ferrone CR, Pieretti-Vanmarcke R, Bloom JP, Zheng H, Szymonifka J, Wargo JA, Thayer SP, Lauwers GY, Deshpande V, Mino-Kenudson M. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012;152:S43-S49. [PMID: 22763261 DOI: 10.1016/j.surg.2012.05.020] [Cited by in Crossref: 136] [Cited by in F6Publishing: 113] [Article Influence: 15.1] [Reference Citation Analysis]
362 Penheiter AR, Deelchand DK, Kittelson E, Damgard SE, Murphy SJ, O'Brien DR, Bamlet WR, Passow MR, Smyrk TC, Couch FJ, Vasmatzis G, Port JD, Marjańska M, Carlson SK. Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. Pancreatology 2018;18:46-53. [PMID: 29170050 DOI: 10.1016/j.pan.2017.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
363 Chakravarty KD, Hsu JT, Liu KH, Yeh CN, Yeh TS, Hwang TL, Jan YY, Chen MF. Prognosis and feasibility of en-bloc vascular resection in stage II pancreatic adenocarcinoma. World J Gastroenterol 2010;16:997-1002. [PMID: 20180240 DOI: 10.3748/wjg.v16.i8.997] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
364 Vanderveen KA, Chen SL, Yin D, Cress RD, Bold RJ. Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis. Cancer. 2009;115:2420-2429. [PMID: 19301434 DOI: 10.1002/cncr.24269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
365 Mortensen MB, Fristrup C, Ainsworth A, Nielsen HO, Pless T, Hovendal C. Combined pretherapeutic endoscopic and laparoscopic ultrasonography may predict survival of patients with upper gastrointestinal tract cancer. Surg Endosc. 2011;25:804-812. [PMID: 20676688 DOI: 10.1007/s00464-010-1258-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
366 Listing H, Mardin WA, Wohlfromm S, Mees ST, Haier J. MiR-23a/-24-induced gene silencing results in mesothelial cell integration of pancreatic cancer. Br J Cancer 2015;112:131-9. [PMID: 25422915 DOI: 10.1038/bjc.2014.587] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
367 Menini S, Iacobini C, de Latouliere L, Manni I, Vitale M, Pilozzi E, Pesce C, Cappello P, Novelli F, Piaggio G, Pugliese G. Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in KrasG12D/+ mice. J Exp Clin Cancer Res 2020;39:152. [PMID: 32778157 DOI: 10.1186/s13046-020-01665-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
368 Yu J, Blackford AL, Dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;Epub ahead of print. [PMID: 25636698 DOI: 10.1136/gutjnl-2014-308653] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 14.0] [Reference Citation Analysis]
369 Abe M, Kondo S, Hirano S, Ambo Y, Tanaka E, Morikawa T, Okushiba S, Katoh H. Long-term survival after radical resection of advanced pancreatic cancer: a case report with special reference to CD8+ T-cell infiltration. Int J Gastrointest Cancer 2003;33:107-10. [PMID: 14716057 DOI: 10.1385/IJGC:33:2-3:107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
370 Jiang CY, Wang W, Yin YL, Yuan ZR, Wang LB. Expression of the adipocytokine resistin and its association with the clinicopathological features and prognosis of pancreatic ductal adenocarcinoma. Oncol Lett. 2012;4:960-964. [PMID: 23162631 DOI: 10.3892/ol.2012.865] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
371 Laheru D, Biedrzycki B, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods Mol Biol. 2013;980:175-203. [PMID: 23359154 DOI: 10.1007/978-1-62703-287-2_9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
372 Lopez NE, Prendergast C, Lowy AM. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014;20:10740-10751. [PMID: 25152577 DOI: 10.3748/wjg.v20.i31.10740] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 54] [Article Influence: 13.7] [Reference Citation Analysis]
373 Hirakawa T, Yashiro M, Murata A, Hirata K, Kimura K, Amano R, Yamada N, Nakata B, Hirakawa K. IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer. BMC Cancer. 2013;13:392. [PMID: 23962053 DOI: 10.1186/1471-2407-13-392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
374 James PD, Meng ZW, Zhang M, Belletrutti PJ, Mohamed R, Ghali W, Roberts DJ, Martel G, Heitman SJ. The incremental benefit of EUS for identifying unresectable disease among adults with pancreatic adenocarcinoma: A meta-analysis. PLoS One 2017;12:e0173687. [PMID: 28319148 DOI: 10.1371/journal.pone.0173687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
375 Verbeke CS. Resection margins in pancreatic cancer. Pathologe 2013;34 Suppl 2:241-7. [PMID: 24196622 DOI: 10.1007/s00292-013-1799-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
376 Ruess DA, Makowiec F, Chikhladze S, Sick O, Riediger H, Hopt UT, Wittel UA. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma. BMC Surg 2015;15:123. [PMID: 26615588 DOI: 10.1186/s12893-015-0110-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 5.2] [Reference Citation Analysis]
377 Choi SH, Kim HJ, Kim KW, An S, Hong SM, Kim SC, Kim MH. DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. Br J Radiol 2017;90:20160403. [PMID: 28339284 DOI: 10.1259/bjr.20160403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
378 Tseng DSJ, Pranger BK, van Leeuwen MS, Pennings JP, Brosens LA, Mohammad NH, de Meijer VE, van Santvoort HC, Erdmann JI, Molenaar IQ. The Role of CT in Assessment of Extraregional Lymph Node Involvement in Pancreatic and Periampullary Cancer: A Diagnostic Accuracy Study. Radiol Imaging Cancer 2021;3:e200014. [PMID: 33817647 DOI: 10.1148/rycan.2021200014] [Reference Citation Analysis]
379 Ma YY, Shi JJ, Chen JB, Xu KC, Niu LZ. Irreversible electroporation for liver metastasis from pancreatic cancer: A case report. World J Clin Cases 2020;8:390-7. [PMID: 32047790 DOI: 10.12998/wjcc.v8.i2.390] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
380 Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST. EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer. Gastrointest Endosc 2017;86:161-9. [PMID: 27889543 DOI: 10.1016/j.gie.2016.11.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 5.4] [Reference Citation Analysis]
381 Téoule P, Rasbach E, Oweira H, Otto M, Rahbari NN, Reissfelder C, Rückert F, Birgin E. Obesity and Pancreatic Cancer: A Matched-Pair Survival Analysis. J Clin Med 2020;9:E3526. [PMID: 33142763 DOI: 10.3390/jcm9113526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Gheewala T, Skwor T, Munirathinam G. Photosensitizers in prostate cancer therapy. Oncotarget 2017;8:30524-38. [PMID: 28430624 DOI: 10.18632/oncotarget.15496] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
383 Beger HG, Rau B, Gansauge F, Leder G, Schwarz M, Poch B. Pancreatic cancer--low survival rates. Dtsch Arztebl Int. 2008;105:255-262. [PMID: 19629206 DOI: 10.3238/arztebl.2008.0255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.2] [Reference Citation Analysis]
384 Dal Molin M, Brant A, Blackford AL, Griffin JF, Shindo K, Barkley T, Rezaee N, Hruban RH, Wolfgang CL, Goggins M. Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. PLoS One 2016;11:e0164195. [PMID: 27732623 DOI: 10.1371/journal.pone.0164195] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
385 Meng Z, Cao M, Zhang Y, Liu Z, Wu S, Wu H. Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis. BMC Gastroenterol 2019;19:59. [PMID: 31014264 DOI: 10.1186/s12876-019-0975-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
386 Koopmann BD, Harinck F, Kroep S, Konings IC, Naber SK, Lansdorp-Vogelaar I, Fockens P, van Hooft JE, Cahen DL, van Ballegooijen M, Bruno MJ, de Kok IM. Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. Int J Cancer. 2021;. [PMID: 33644856 DOI: 10.1002/ijc.33540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
387 Li AE, Li BT, Ng BHK, McCormack S, Vedelago J, Clarke S, Pavlakis N, Samra J. Diagnostic Accuracy of Imaging Modalities in the Evaluation of Vascular Invasion in Pancreatic Adenocarcinoma: A Meta-Analysis. World J Oncol 2013;4:74-82. [PMID: 29147335 DOI: 10.4021/wjon657w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
388 Riall TS, Sheffield KM, Kuo YF, Townsend CM, Goodwin JS. Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. J Am Geriatr Soc. 2011;59:647-654. [PMID: 21453378 DOI: 10.1111/j.1532-5415.2011.03353] [Reference Citation Analysis]
389 Ammori BJ, Ayiomamitis GD. Laparoscopic pancreaticoduodenectomy and distal pancreatectomy: a UK experience and a systematic review of the literature. Surg Endosc 2011;25:2084-99. [PMID: 21298539 DOI: 10.1007/s00464-010-1538-4] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 7.2] [Reference Citation Analysis]
390 Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17:192-200. [PMID: 22250057 DOI: 10.1634/theoncologist.2011-0268] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 6.0] [Reference Citation Analysis]
391 Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys. 2011;81:1328-1335. [PMID: 20934270 DOI: 10.1016/j.ijrobp.2010.07.1993] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]